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ABSTRACT 
 
NF-κB inducing kinase (NIK, also known as MAP3K14) is a serine/threonine protein-
kinase that is crucial for activation of the non-canonical NF-κB signaling pathway. Although 
NIK has been shown to promote tumorigenesis in several cancers by increasing cell proliferation 
and survival, the molecular mechanisms underlying the role of NIK in regulating glioma 
pathogenesis remain poorly understood. While NIK is described as being primarily cytosolic, in 
this study, we found that a discrete pool of NIK is predominantly localized to mitochondria in 
patient-derived glioma cells, ex vivo tumor tissue, and mouse embryonic fibroblasts (MEFs). 
Depletion of NIK using CRISPR/Cas9-mediated genome editing causes diminished invasion in 
three-dimensional collagen matrices and also results in morphological alterations of 
mitochondria, which appear entangled and clustered in perinuclear regions. Analysis of 
mitochondrial trafficking in living cells revealed that NIK promoted mitochondria velocity and 
subcellular distribution to the leading edge of migrating glioma cells. Importantly, NIK enhances 
mitochondrial recruitment of dynamin related protein 1 (Drp1), a key component of 
mitochondrial fission machinery, to promote mitochondrial fragmentation and glioma cell 
invasion. NIK interacts with Drp1 at mitochondria, rather than in the cytoplasm. Particularly, 
NIK accumulated transiently on dividing mitochondria, where it binds to Drp1 at mitochondrial 
constriction at fission sites. Notably, NIK regulation of mitochondrial dynamics, glioma cell 
invasion, and tumor growth requires its kinase activity, but occurs independently of its 
established downstream targets, IB kinase (IKK) / and NF-κB activation. Additionally, NIK 
kinase activity is critical to promote phosphorylation of Drp1 at serine 616, which is important 
for its fission-promoting function. Our results establish a new paradigm for IKK-independent 
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NIK signaling at mitochondria and significantly expand the current dogma that NIK is mainly 
cytosolic and exclusively regulates NF-κB activity. Overall, these findings highlight the 
importance of NIK in tumor pathogenesis and invite new therapeutic strategies that attenuate 
mitochondrial dysfunction through inhibition of NIK. 
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NOMENCLATURE 
 
ADP    Adenosine diphosphate  
ATP    Adenosine triphosphate  
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EDTA   Ethylenediaminetetraacetic acid 
ER    Endoplasmic reticulum  
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ERK2        Extracellular-signal-regulated kinase 2 
ETC    Electron transport chain  
FADH2  Flavin adenine dinucleotide  
Fis1   Mitochondrial fission 1 protein 
Fn14   Fibroblast growth factor-inducible 14  
GBM   Glioblastoma multiforme   
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GFP        Green fluorescent protein 
HA          Hemagglutinin 
HCI    Hydrochloric acid  
IgG    Immunoglobulin G  
IKKα/β   IkappaB kinase α/β  
IL-1R    Interleukin 1 receptor  
IMM    Mitochondrial membrane  
IκB    IkappaB  
LTβR    Lymphotoxin-β receptor  
MAM    Mitochondria-associated membrane  
MAVS   Mitochondrial antiviral signaling  
MDV    Mitochondrial-derived vesicles  
MEFs    Mouse embryonic fibroblasts  
Mff    Mitochondria fission factor  
Mfn1   Mitofusin 1  
Mfn2   Mitofusin 2  
MID49  Mitochondrial dynamics protein of 49 kDa  
MID51  Mitochondrial dynamics protein of 51 kDa 
Miro1   Mitochondrial Rho GTPase 1  
mito-PAGFP   Mitochondrial matrix-targeted photoactivatable green fluorescent protein   
MOM    Mitochondrial outer membrane  
mtDNA   Mitochondrial DNA 
mTOR   Mechanistic target of rapamycin  
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MTS    Mitochondrial targeting sequence  
NADH   Nicotinamide adenine dinucleotide  
NF-κB   Nuclear Factor-kappaB  
NIK    NF-κB inducing kinase  
OPA1   Optic Atrophy 1  
OXPHOS   Oxidative phosphorylation  
PAMPs   Pathogen-associated molecular patterns 
PGAM5  Phosphoglycerate mutase family member 5  
PLA    Proximity ligation assay  
RHD    Rel homology domain  
ROI   Regions of interest  
ROS    Reactive oxygen species  
SDS        Sodium dodecyl sulfate 
SR-SIM   Superresolution-structured illumination microscopy  
TLR4   Toll-like receptor 4  
TNF    Tumor necrosis factor  
TNFR    Tumor necrosis factor receptor 
TRAF    TNF receptor-associated factor  
TWEAK   Tumor necrosis factor-like weak inducer of apoptosis  
WT   Wild type 
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CHAPTER I  
INTRODUCTION  
 
1.1 Glioblastoma multiforme (GBM) 
 Glioblastoma multiforme (Glioblastoma) is the most malignant and aggressive primary 
tumors in the adult central nervous system (CNS). Glioblastoma originates from star-shaped glial 
cells including oligodendrocytes and astrocytes, which mainly provide support functions for 
neurons.  According to the National Cancer Institute, the average annual incidence rate of 
glioblastoma is two to three per 100,000 adults per year and glioblastoma accounts for 
approximately 17 percent of all brain tumors in the United States. Despite development of 
effective treatments, current intervention such as surgery, radiation therapy, and chemotherapy 
for glioblastoma extend overall median survival only up to 1.5 years due to therapeutic resistance 
and tumor recurrence after surgical removal. Thus, glioblastoma is classified as a WHO Grade 
IV (Grade I-least malignant to Grade IV-most malignant). 
As a hallmark, tumor heterogeneity at the genetic level within individual tumors 
contributes to distinct tumorigenic potential that significantly influence tumor progression and 
outcome of the tumor in response to treatment (Calderwood, 2013; Lawrence et al., 2013; Longo, 
2012). Deregulation of intracellular signaling such as mechanistic target of rapamycin (mTOR), 
Erb-B2 Receptor Tyrosine Kinase 2 (ErbB2), and nuclear factor kappa B (NF-κB) in 
malignancies is frequently observed and allows cancers cells to acquire resistance to cell death 
and uncontrolled growth and proliferation (Guertin and Sabatini, 2007; Xia et al., 2014; Yu and 
Hung, 2000). In addition, the major characteristic of glioblastoma malignancy is diffuse invasion 
into adjacent normal brain tissue and migration to a significant distance from the primary tumor 
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area that is a fundamental step in metastasis (Valastyan and Weinberg, 2011; van Zijl et al., 
2011). This characteristic is one of the most difficult challenges to therapeutically target. 
Therefore, a clear understanding of the cellular and molecular mechanisms underlying the tumor 
pathogenesis is crucial for the development of specific therapeutic strategies against malignant 
glioblastoma. 
 
1.2 NF-κB pathways    
1.2.1 NF-κB 
About thirty years ago, NF-κB was discovered by Sen and Baltimore, as a transcription 
factor that specifically recognizes and binds to the enhancer element of the immunoglobulin 
kappa light-chain of activated B lymphocytes (Sen and Baltimore, 1986). NF-κB comprises a 
family of five transcription factors, which contains of NF-κB1 (p105/p50), NF-κB2 (p100/p52), 
RelA (p65), RelB, and c-Rel (Baldwin, 1996; Ghosh et al., 1998). Interestingly, these proteins 
share a highly conserved Rel homology domain (RHD) essential for nuclear localization, 
dimerization and DNA binding. Based on sequences C-terminal to the RH domain, the NF-κB 
proteins can be divided into two distinct classes. One class includes RelA, RelB, and c-Rel have 
a C-terminal transactivation domain, and the other class includes NF-κB1 p105 and NF-κB2 
p100 proteins, which are characterized by inhibitory multiple ankyrin repeats at C-terminal 
regions, and undergo proteolytic processing to yield p50 and p52, respectively (Betts and Nabel, 
1996; Fan and Maniatis, 1991; Heusch et al., 1999). Homodimeric complexes of p50 or p52 can 
repress transcription through binding to NF-κB elements of gene promoters, whereas RelA, 
RelB, and c-Rel contain transcription activation domains that interact with either p52 or p50 to 
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bind DNA and activate gene transcription (Hayden and Ghosh, 2012; Moynagh, 2005; 
Oeckinghaus and Ghosh, 2009). 
NF-κB pathway can be activated by various stimuli, such as growth factors, cytokines, 
and reactive oxygen species (ROS), in various cells (Oeckinghaus et al., 2011; Siebenlist et al., 
1994) (Fig. 1). Extensive studies have revealed that NF-κB pathway plays critical roles in 
immune, inflammatory, cell growth, differentiation, and apoptotic processes through regulating 
the expression of many genes (Aggarwal, 2004; Ghosh et al., 1998; May and Ghosh, 1998). 
Importantly, NF-κB signaling is constitutively activated in various tumor types (Jost and Ruland, 
2007; Karin, 2006). The aberrant constitutive activation of NF-κB in human cancers contributes 
to malignant progression and therapeutic resistance (Jost and Ruland, 2007; Perkins, 2012). 
Therefore, a clear understanding of NF-κB functions underlying tumor pathogenesis is crucial 
for the development of specific therapy strategy against malignant tumor. 
 
1.2.2 Canonical and non-canonical NF-κB pathway 
Two distinct NF-κB signaling pathways are tightly controlled by a complex network of 
positive and negative regulatory elements at multiple levels (Fig. 1). The canonical NF-κB 
pathway is triggered by the activation of various cell surface receptors such as tumor necrosis 
factor receptor (TNFR), interleukin 1 receptor (IL-1R), pathogen-associated molecular patterns 
(PAMPs), some danger-associated molecular patterns (DAMPs), and Toll-like receptor 4 (TLR4) 
through binding with their proinflammatory ligands (Oeckinghaus et al., 2011; Shih et al., 2011). 
Under activating conditions with cytokines, inactive NF-κB1/RelA family members sequestered 
in the cytoplasm are release from inhibitory IkappaB (IκB) proteins through recruited IkappaB 
kinase complex (IKKα, IKKβ, and IKKγ)-mediated IκB phosphorylation, which results in 
 4 
 
ubiquitination and proteasomal degradation of the IκB proteins. Consequently, the free NF-κB 
dimers translocate to the nucleus to activate expression of target genes (Oeckinghaus and Ghosh, 
2009; Wertz and Dixit, 2010). 
In contrast, the non-canonical NF-κB pathway is only activated by a subset of receptors 
including lymphotoxin-β receptor (LTβR), CD30 ligand (CD30L), CD40 ligand (CD40L), BAFF 
receptor (BR3), and Fibroblast growth factor-inducible 14 (Fn14) (Hayden and Ghosh, 2012; 
Razani et al., 2011; Sun, 2011). Upon stimulation with tumor necrosis factor (TNF) family 
cytokines, stabilized NF-κB inducing kinase (NIK) phosphorylates and activates IKKα 
homodimers, which leads to phosphorylation of sequestered NF-κB member, NF-kB2 p100 
associated with RelB, and proteolytic processing of precursor protein p100 to generate mature 
p52 (Ling et al., 1998; Sun, 2017). Finally, the NF-κB p52/RelB complexes translocate to the 
nucleus, leading to transcription of target genes (Sun, 2012). Thus, unlike canonical NF-κB 
pathway, the non-canonical pathway is largely depending on NIK-mediated phosphorylation of 
IKKα to promote NF-κB2/p100 processing, which does not depend on IKKβ or IKKγ for 
degradation of the inhibitory IκB proteins. 
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Figure 1. NF-κB pathway can be activated via two major signal transduction pathways. Canonical NF-κB 
pathway: under stimulated conditions, the IκB molecules are phosphorylated by the IKK complex, which leads to 
proteasomal degradation of IκB. RelA:p50 heterodimer are translocate to the nucleus, resulting in target genes 
expression involved in immune and inflammatory responses, developmental processes, cellular growth and 
apoptosis. Non-canonical NF-κB pathway: stabilized NIK by receptor ligation activates IKKα, which leads to 
processing of p100 to generate p52 and nuclear translocation of RelB:p52 heterodimers for activation of 
transcription of target genes involved in survival of premature B cells, lymphoid organogenesis, and humoral 
immunity. 
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1.3 NF-κB inducing kinase (NIK) 
1.3.1 Structure and turnover of NIK 
Non-canonical NF-κB pathway requires serine/threonine protein kinase NIK (also known 
as MAP3K14; mitogen-activated protein kinase kinase kinase 14), which phosphorylates IKKα 
and induces the processing of the precursor protein p100 into p52 and subsequently activates 
RelB-p52-driven NF-κB signaling. As a central regulatory component of the non-canonical NF-
κB pathway, NIK has been extensively studied for its roles in regulating homeostasis and 
maturation of B cell and lymphoid organ development (Fagarasan et al., 2000; Hahn et al., 2016; 
Sasaki et al., 2008; Senftleben et al., 2001). The human NIK gene encodes 947 amino acid 
residues and is known to contain at least four functional domains: N-terminal TRAF3-binding 
domain (aa30 - aa120), a negative regulatory domain (aa121 - aa318), a central serine/threonine 
kinase domain (aa390 - aa660), and a C-terminal non-catalytic region (aa660 - aa947) (Liao G 
2004; Xiao G 2000) (Fig.2). The sequence of NIK is highly conserved and identical to the 
corresponding amino acids of a variety of species (human NIK residues is >80% identical with 
mouse 84%, rat 85%, bovine 88%, and rabbit 87%) (Fig.3). Interestingly, a study examining the 
structure of NIK revealed that NIK activation doesn’t require its inducible phosphorylation, 
rather it requires a catalytically important salt bridge between Lys429 and Glu440 to stabilize 
active conformation (Tao and Ghosh, 2012). In fact, NIK containing alanine mutations at Lys429 
and Lys430 is unable to promote processing of p100 for activation of non-canonical NF-κB 
signaling (Sheng et al., 2012; Sylla et al., 1998). 
Under resting conditions, NIK is constitutively ubiquitylated and degraded by K48-linked 
polyubiquitylation through E3 ligase complex including TNF receptor-associated factor 
(TRAF)2/3 and cellular inhibitor of apoptosis (cIAP)1/2, resulting very low intracellular 
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concentrations of NIK (Liao et al., 2004; Tao and Ghosh, 2012; Thu and Richmond, 2010) 
(Fig.4). After stimulation with TNF family cytokines such as a tumor necrosis factor-like weak 
inducer of apoptosis (TWEAK, also known as TNFSF12), NIK-TRAF3-TRAF2-cIAP complex 
is recruited to the receptor. Then, the receptor-induced ligase activity of TRAF2 results in K63-
specific ubiquitination of cIAP, leading to K48-linked ubiquitination and proteasomal 
degradation of TRAF3 as a key NIK-associated protein. Consequently, stabilized and 
accumulated NIK activates non-canonical NF-κB pathway through phosphorylation of IKKα for 
triggering p100 processing (Hacker et al., 2012; Sun, 2010) (Fig.4). 
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Figure 2. Structure of human NIK protein. Human NIK contains four main domains, including a TRAF3-binding 
domain, negative regulatory domain, kinase domain and non-catalytic domain. 
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Figure 3. NIK protein sequence alignment. Amino acid sequences of NIK are highly conserved between species. 
Human - mouse 84%; - rat 85%; - bovine 88%; - rabbit 87%. The multiple sequence alignment analysis was done 
through ClustalX. 
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Figure 4. Posttranslational regulation of NIK. Under unstimulated conditions, the E3 ligase complex 
(TRAF2:TRAF3:cIAP1:cIAP2) direct ubiquitination and proteasomal degradation of NIK, resulting in low 
intracellular concentration of NIK below the threshold. Upon stimulation, NIK-E3 ligase complex is recruited to the 
receptor, leading to degradation of TRAF3 and release newly synthesized NIK. NIK-mediated phosphorylation of 
IKKα triggers the p100 processing and nuclear translocation of p52:RelB dimers for target gene expression. 
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1.3.2 Roles for NIK in cancer 
Since NIK was originally identified as NF-κB-activating protein kinase interacting with 
TRAF2 (Natoli et al., 1997), many studies demonstrated that NIK is involved in many of the key 
cellular processes necessary for stem cell behaviors such as differentiation, development, and 
embryogenesis (Kajiura et al., 2004; Shinkura et al., 1999; Vaira et al., 2008; Yang et al., 2010; 
Yin et al., 2001). Aberrant activation of non-canonical NF-κB pathway comprising NIK-IKKα-
p100 axis is commonly observed in human malignancies (Annunziata et al., 2007; Bennett et al., 
2017; Cogswell et al., 2000; Keats et al., 2007; Nadiminty et al., 2008). Moreover, deregulation 
of the signaling pathway contributes to pathologic features of malignancies such as enhanced 
invasion, metastasis, and tumorigenicity (Ge et al., 2016; Tchoghandjian et al., 2013). Recently, 
there has been growing interest in roles of NIK in cancers. NIK is frequently overexpressed in 
human cancers including ovarian cancer, breast cancer, melanoma, pancreatic cancer, and lung 
cancer (Doppler et al., 2013; Saitoh et al., 2010; Thu et al., 2012; Uno et al., 2014; Yamamoto et 
al., 2013). NIK has been shown to promote tumorigenesis in cancers through its ability to 
promote cell proliferation and survival as anti-apoptotic and pro-survival functions (Thu et al., 
2012; Xia et al., 2014). In particular, our previous studies have investigated the correlation 
between NF-κB pathway and invasiveness of glioma cells derived from surgical samples of 
GBM patients in a three-dimensional collagen I matrix. We observed that NIK-dependent non-
canonical NF-κB pathway is significantly increased in highly invasive glioma cell lines 
compared to less invasive glioma cell lines (Cherry et al., 2015; Lee et al., 2013). More recently, 
we have shown that the ability of NIK to promotes glioma invasiveness is associated with cell 
shape changes including formation of extensive actin-rich membrane protrusions, termed 
invadopodia, which is related with degradation of the extracellular matrix (ECM) for tumor 
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migration and invasion (Duran et al., 2016). However, the role of NIK in CNS tumor 
pathogenesis, and the molecular mechanisms underlying NIK-mediated malignant characteristics 
in glioblastoma are still largely unknown. 
 
1.4 Mitochondria 
1.4.1 Mitochondria and mechanisms regulating mitochondrial dynamics 
Since anatomist Von Kölliker first described granular structures in muscle cells in 1856, 
many scientists identified the organelle under the light microscope that was later named 
mitochondria by Benda in 1898 (Lehninger, 1964; Margulis, 1970). Mitochondria are double 
membrane-bound subcellular organelles found in the cytoplasm of nearly all eukaryotic cells and 
contain a small amount of their own DNA, known as mitochondrial DNA (mtDNA) that retains 
13 of the most important oxidative phosphorylation (OXPHOS) genes for adenosine triphosphate 
(ATP) production. The mitochondrial ATP production depends on the electron transport chain 
(ETC) consisting of respiratory chain complexes I - IV within mitochondrial inner membrane 
(MIM), which pumps nicotinamide adenine dinucleotide (NADH) and flavin adenine 
dinucleotide (FADH2) produced in the citric acid cycle and glycolysis. The ETC generates a 
proton gradient across the MIM to convert adenosine diphosphate (ADP) into energy molecule 
ATP for many vital cellular functions (Benard et al., 2010; Bhargava and Schnellmann, 2017). 
Mitochondria are highly dynamic organelles that continuously fuse, divide, and migrate. 
The dynamics of mitochondrial morphology is tightly regulated by a balance between 
mitochondrial fusion and fission machineries that adapt to cellular metabolic demands during 
cell proliferation, differentiation, division and survival (Kageyama et al., 2012; Khacho et al., 
2016; Mils et al., 2015). Fission results in mitochondrial fragmentation into short rods or spheres, 
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while fusion causes long filamentous mitochondrial morphology. These morphological changes 
of mitochondria also contribute to a quality control mechanism that preserve healthy 
mitochondria and remove damaged mitochondria (Ni et al., 2015; Twig et al., 2008). In 
mammalian cells, mitochondria fission is mediated by dynamin-related protein 1 (Drp1). The 
cytosolic Drp1 is recruited to mitochondria through binding with mitochondrial outer membrane 
(MOM) proteins including Mitochondrial fission 1 protein (Fis1), mitochondria fission factor 
(Mff), mitochondrial dynamics protein of 49 kDa (MID49) and 51 kDa (MID51), resulting in 
generating the constriction force for division of mitochondria (Elgass et al., 2013; Palmer et al., 
2013). Mitochondrial fusion is mediated by three large GTPases including mitofusin 1 (Mfn1), 
mitofusin 2 (Mfn2) and Optic Atrophy 1 (OPA1). Mfn1 and Mfn2 are involved in MOM 
tethering of neighboring mitochondria to facilitate membrane fusion, while OPA1 is localized on 
MIM and facilitates MIM fusion (Zhang and Chan, 2007). 
 
1.4.2 Mitochondrial dynamics in cancer  
In early 1900s, physiologist Otto Warburg first suggested that mitochondria may play an 
important role in the development of cancer through constitutively upregulation of glucose 
metabolism, but not by OXPHOS, to produce most ATP even under anaerobic conditions for cell 
survival (Warburg et al., 1931). Warburg's observation is known as the ‘Warburg effect’ 
(enhanced aerobic glycolysis), and described that metabolic shift towards aerobic glycolysis in 
cancer cells increased glucose uptake to synthesize enough ATP for several proliferative and 
survival advantages. Aerobic glycolysis also known to causes local acidification of tumor 
microenvironment, which leads to changes in intracellular pH that facilitate tumor invasion 
(Swietach et al., 2007). In addition, increased ROS caused by impaired oxidative 
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phosphorylation in cancer lead to progression of the cancer (Singh et al., 2009; Weinberg et al., 
2010). Therefore, metabolic imbalances and mitochondrial dysfunction are major hallmarks of 
cancer cells (Boland et al., 2013; Galluzzi et al., 2006). 
The dynamic network, which includes changes in size and subcellular distribution of 
mitochondria, is tightly regulated through mitochondrial dynamic machinery (Chan, 2006). 
Alteration of mitochondrial dynamics caused by imbalance between mitochondrial fusion and 
fission events potentially contribute to dysregulation of various cellular processes, which have 
been implicated in tumorigenesis (Grandemange et al., 2009; Liesa et al., 2009; Liu et al., 2004; 
Maycotte et al., 2017). Interestingly, recent studies revealed that mitochondria in human invasive 
breast carcinoma and oncocytic thyroid tumors were more fragmented, compared to non-
malignant tumors (Ferreira-da-Silva et al., 2015; Zhao et al., 2013). In these tumors, expression 
of mitochondrial fission regulator Drp1 is highly upregulated and its genetic and 
pharmacological inhibition suppressed cell migration and invasion. A similar phenotype that 
enhanced mitochondrial fragmentation and expression of Drp1 were also observed in brain tumor 
initiating cells (BTICs), compared with non-BTICs. Targeting Drp1 using genetic and 
pharmacological approaches inhibited tumor growth and induced apoptosis (Xie et al., 2015). 
Thus, current studies on cancer have shed light on physiological roles of mitochondria in cancer 
cells that emphasize the importance of mitochondrial dynamics. Nonetheless, the molecular 
mechanisms underlying relationships between mitochondrial dynamics and tumor 
invasion/migration are still poorly understood. 
 
1.4.3 Mitochondrial fission regulator, Dynamin-related protein 1  
            Drp1 is a member of the dynamin family of GTPases that regulates mitochondrial fission 
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in mammals. Upon the initiation of fission, the GTPase is translocated from the cytosol to the 
mitochondrial outer membrane through binding to its mitochondrial receptors including Fis1, 
Mff, Mid49, and Mid51 (Loson et al., 2013; Smirnova et al., 2001). Membrane-bound Drp1 
undergoes oligomerization, wraps around potential fission sites, and sequentially constricts the 
mitochondrial membrane in the presence of GTP (Ji et al., 2015; van der Bliek et al., 2013) 
(Fig.5). The activity of Drp1 can be controlled by post-translational modifications, such as 
phosphorylation, sumoylation, S-nitrosylation and ubiquitination (Elgass et al., 2013; Otera et 
al., 2013). Particularly, its activity is differently regulated by two major phosphorylation sites, 
serine 616 (S616) and serine 637 (S637) (Benard et al., 2010; Jahani-Asl and Slack, 2007; 
Taguchi et al., 2007). Phosphorylation at S616 of Drp1 promotes mitochondrial fission, whereas 
S637 phosphorylation resulted in loss of its activity. Furthermore, multiple serine/threonine 
protein kinases including cAMP-dependent protein kinase (PKA), calcium calmodulin-
dependent protein kinase (CAMK), and cyclin-dependent kinase (CDK) have been identified to 
regulate Drp1 activity (Chang and Blackstone, 2007a; Cho et al., 2014; Strack et al., 2013). 
Recent studies revealed that extracellular-signal-regulated kinase (Erk2)-mediated 
phosphorylation at S616 of Drp1 promotes mitochondrial fission, contributing to mitogen-
activated protein kinase (MAPK)-driven tumor growth (Kashatus et al., 2015; Serasinghe et al., 
2015). Based on the observation that excessive mitochondrial fission with upregulated Drp1 
activity in cancers, regulation of intracellular localization and phosphorylation of Drp1 should be 
a key regulatory approach to prevent tumor progression through controlling mitochondrial 
dynamics.  
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Figure 5. Role of Drp1 in mitochondrial fission. Mitochondrial fission requires the function of dynamin-related 
protein Drp1. Cytoplasm-localized Drp1 is recruited to pre-determined sites on mitochondrial outer membrane and 
oligomerized. The oligomerized Drp1 induces constriction of the fission site through GTP hydrolysis. 
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1.5 Dissertation goals 
The NF-κB family of transcription factors is known to play crucial roles in the 
development of multiple malignancies through regulating inflammation, proliferation and 
survival (Ben-Neriah and Karin, 2011). In fact, constitutive activation of NF-κB signaling has 
been observed in various tumor types (Jost and Ruland, 2007; Karin, 2006). The NF-κB 
pathways are classified into two distinct pathways: canonical and the non-canonical pathway. 
Most studies investigating the effects of NF-κB signaling on tumorigenesis have been focused on 
the canonical signaling pathway, while roles of non-canonical NF-κB signaling pathway in 
cancers are very poorly understood. In particular, NIK as a central signaling component of the 
non-canonical pathway, undergoes constitutive proteasomal degradation and consequently 
results in biochemically undetectable levels of NIK in unstimulated normal cells. In contrast, 
NIK expression was significantly elevated in breast cancer, multiple myeloma and inflammatory 
diseases (Annunziata et al., 2007; Enzler et al., 2006; Yamaguchi et al., 2009). In our previous 
studies, we demonstrated that non-canonical NF-κB signaling can promote glioma tumor (Cherry 
et al., 2015), particularly NIK is both necessary and sufficient for glioma cell invasion through 
promoting extensive membrane branching and elongated invadopodia protrusions independently 
of canonical NF-κB signaling (Duran et al., 2016). 
Mitochondria are specialized cellular compartments that are involved in various functions 
including energy production, apoptosis and cell proliferation. Altered mitochondrial dynamics by 
imbalance between fusion and fission is known to contribute to tumorigenesis. Importantly, 
canonical NF-κB proteins have been shown to be localized in mitochondria that regulate 
mitochondrial functions (Cogswell et al., 2003; Johnson et al., 2011). Moreover, non-canonical 
NF-κB signaling has been recently implicated in mitochondrial biogenesis and regulation of 
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mitochondrial network morphology (Laforge et al., 2016; Millet et al., 2013; Zeng et al., 2015). 
However, roles of NIK in regulating mitochondrial dynamics to promote tumor progression have 
never been explored. Given this information, we hypothesize that NIK is localized to 
mitochondria and regulates mitochondrial dynamics, which are required for acquisition of 
tumorigenic phenotype in glioma. This project will seek to address new roles of NIK, more 
specifically the molecular mechanisms controlling mitochondrial morphology associated with 
pathogenesis of tumor cells, and it may contribute to the development of new therapies for 
cancers. 
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CHAPTER II  
 METHODS AND MATERIALS 
 
2.1 Cell culture and reagents 
BT25 and BT114 cell lines were obtained from human glioma patients as previously 
described (Kelly et al., 2009). These cell lines were maintained as spheroids in Neural Stem Cell 
(NSC) medium containing DMEM/F-12, 1X B-27 supplement minus Vitamin A, 1X Glutamax, 
25 ng/ml EGF, 25 ng/ml bFGF and 1X Pen/Strep (Life Technologies). 293T cells were obtained 
from ATCC. IKK MEFs were a kind gift from Dr. Baldwin (originally from Dr. Verma). MEFs 
and HEK293T were cultured in DMEM medium with 10 % FBS and 1X Pen/Strep. MDA-
MB231 and Panc1 were from ATCC (Manassas, VA) and cultured in RPMI medium with 10% 
FBS and 1X Pen/Strep. All cells were cultured at 37 °C with 95 % humidity and 5 % CO2.  
 
2.2 Reagents  
For immunostaining, the following primary antibodies were purchased: NIK (ab191591 
or ab7204, for Figure S2A); IKKα (ab32041); Tom20-AF647 (ab205487); Sec61A-AF488 
(ab205794); Drp1 (ab56788) from Abcam, Cambridge, MA, USA and Drp1 (8570S); p-Drp-
S616 (CST4494) from Cell Signaling Technology, Danvers, Ma, USA and Tim50 (sc-393678) 
from Santa Cruz Biotechnology, Dallas, Tx, USA. For immunoblot analyses, the following 
antibodies were obtained: MFF (ab81127); Fis1 (ab156865); Opa1 (ab157457) from Abcam and 
                                                 
Part of this chapter is reprinted with permission from “NIK/MAP3K14 Regulates Mitochondrial Dynamics and 
Trafficking to Promote Cell Invasion.” By Jung JU, Ravi S, Lee DW, McFadden K, Kamradt ML, Toussaint LG, 
Sitcheran R, 2016. Current Biology, 26, 3288-3302, Copyright 2016 by Elsevier Ltd. 
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IKKα (CST2682); IKK (CST2684); NIK (CST4994); Drp1 (CST8570); CoxIV (CST11967); 
Tom20 (CST42406); NFKB2 (CST4882); Mfn-1 (CST14739); Mfn-2 (CST11925) from Cell 
Signaling Technology. The following antibodies were purchased from Santa Cruz 
Biotechnology: GAPDH (sc137179), and β-actin (sc69879).  The following antibodies were 
obtained from Cell Signaling Technology: p-Drp-S637 (CST4867S); p-Drp-S616 (CST3455S) 
for Flow Cytometry. Cellight®  Mitochondria-RFP, BacMam 2.0 (Mito-RFP, C10601) was 
purchased from Life Technologies, Grand Island, NY, USA.  MG132 (#2194S) was purchased 
from Cell Signaling Technology.  Collagen type I (#354249) was purchased from Corning, 
Corning, NY, USA.  rhTWEAK (#310-06) was obtained from PeproTech, Rocky Hill, NY, 
USA. 
 
2.3 Plasmids construction for NIK overexpression 
Human (hNIK) or mouse (mNIK) cDNA was cloned into pLenti6-V5-DEST (Addgene, 
Cambridge, MA) using the GATE-WAYTM Cloning System (Invitrogen). Luciferase (Promega, 
Madison, WI) coding sequences were subcloned into pLenti6-v5-DEST (Invitrogen) and served 
as a control vector for NIK overexpression.  
 
2.4 CRISPR-Cas 9 gene knockout 
NIK: Oligos encoding sg RNAs for human NIK (sgNIK-1: 
GCUCCUUCGGAGAGGUGCAC, sgNIK-2: GAAAGCGUCGCAGCAAAGCC, sgNIK-3: 
AGUACCGAGAAGAAGUCCAC) and sgRNAs for mouse NIK (sgNIK-4: 
AGGAUGGGGCAUUCCGCUGU sgNIK-5: UGGAGCGCAUGCACCAGGUA, sgNIK-6: 
AGUAUCGAGAAGAGGUCCAC) were cloned into Lenti-CrispR-v2 (Addgene) respectively. 
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BT25, WT MEFs, IKK MEFs, Panc1 and MDA-MB231 cells were transduced with a mixture 
of lentiviruses carrying the three mice or human sgRNAs. Loss of NIK expression was 
confirmed by immunoblot, pPCR and/or immunofluorescence microscopy analysis of 
puromycin-resistant cells. BT25-sgNIK cells and sgNIK-MEFs, single colony cells were isolated 
by serial dilution and experiments were repeated with at least two clones. Panc1-sgNIK and 
MDA-MB231-sgNIK cells were analyzed as mixed clones. For controls, cells were transduced 
with empty LentiCrispR-V2. Drp1: Oligos encoding sgRNAs for human Drp1 (sgDrp-1: 
GUUCCCACUACGACGAUUUG, sgDrp1-2: GCUGCCUCAAAUCGUCGUAG, sgDrp1-3:  
GUGACAAUUCCAGUACCUCU) were cloned into Lenti-CrispR-v2. BT25 cells were 
transduced with a mixture of three lentiviruses carrying the human sgRNAs and selected against 
puromycin then subjected to screen Drp1 null by serial dilution.  
 
2.5 Lentivirus production 
Twenty-four μg of lentiviral plasmids and 72 g of polyethyleneimine were used to 
transfect 293T cells. After 3 days of transfection, viral supernatant was harvested and filtered 
through 0.45 µM syringe filter. After filtration, viral particles were concentrated 20-fold to 500 
µl using Lenti-X Concentrator (#631231, Clontech, Mountain View, CA), and 100 µl of 
concentrated virus were used to infect cells. Stably transduced cells were selected for 72 h in 
medium containing 0.6 μg/ml puromycin or 3 μg/ml blasticidin (Invitrogen).   
 
2.6 Three-dimensional collagen invasion assay 
Invasion assays were performed as previously described (Cherry et al., 2015; Lee et al., 
2013). Briefly, collagen type I (Corning, NY) was diluted to 2 mg/ml in DMEM/F-12 medium 
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(1X Pen/Strep) and matrices polymerized in 96-well plates. 4 x 105 cells cultured in NSC or 
NSC+10 % serum were seeded in triplicate in 100μl DMEM/F-12 (1x Pen/Strep, 1X Glutamax) 
without growth factors or serum. Cells were fixed with 3 % glutaraldehyde solution after 48 
hours of invasion and stained with 0.1 % toluidine blue. Invasion density was quantified by 
counting cells below the plane of the monolayer by bright-field light microscopy using a 10 X 10 
ocular grid at 10X or 20X magnification corresponding to a 1 mm2   field. Numbers in at least 
three equivalent, random fields were counted (n = 3 wells each) and normalized to the 
corresponding control. All experiments were performed at least three times. 
 
2.7 Immunofluorescence staining 
2 x 104 cells were seeded in 8 well chamber slides (#80827, Ibidi, Munich, Germany) or 
on coverslips in the presence of 0.5 % FBS and allowed to adhere for 4 hours. Cells were 
transfected with Mito-RFP (for mitochondrial labelling, Invitrogen, C10508) for 16 h, fixed with 
4 % paraformaldehyde, permeabilized for 20 minutes with 0.3 % Triton X-100 in PBS, and 
blocked 30 min at room temperature with 5 % serum corresponding to secondary antibody host. 
Cells were incubated overnight in 0.1 % Triton X-100, 1 % BSA in PBS at 4 °C with primary 
antibody. Cells were then incubated in 1 % BSA for 1 h at room temperature with secondary 
antibody Alexa Fluor 488 (A11008) or Alexa Fluor 594 (A11005) from Life Technologies.  Dual 
immunostaining was performed sequentially; cells were incubated with the first primary 
antibody in 1 % BSA overnight at 4 °C, washed three times with PBS and incubated with the 
corresponding secondary antibody in 1 % BSA for 1 h at room temperature in dark. After 
washing three times with PBS, cells were blocked for a second time with corresponding host 
serum (5 %) for 30 minutes at room temperature. Cells were then incubated with the second 
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primary antibody from a different species, followed by the appropriate secondary antibody. For 
immunostaining with two rabbit antibodies, we used either commercially pre-labeled antibodies, 
or custom-labeled antibodies generated with an antibody labeling kit (Invitrogen, A20181). The 
pre-labeled antibody was always used last. Cells were counter stained with the nuclear stain 
DAPI (Invitrogen, P36931), and phalloidin (Invitrogen, A22287) as indicated. 
 
2.8 Human glioma ex-vivo tissue staining 
The use of de-identified human glioblastoma tissue samples were approved by the 
Institutional Review Boards (IRBs) of both St. Joseph Regional Health Center, Bryan, TX 
(IRB2012-001) and Texas A&M University (IRB2014-0318D). Ex-vivo tissue was immediately 
snap-frozen in OCT on dry ice. Sections of human glioma biopsy samples were fixed with 4 % 
paraformaldehyde and immunostained with antibodies specific for NIK, IKKα and Drp1 (see 
immunofluorescence staining above). 
 
2.9 Image acquisition 
Images were acquired with a Nikon TI A1R inverted confocal microscope with CFI60 
Plan Apochromat Lambda 60x oil immersion objective lens. The Zeiss ELYRA S.1 super-
resolution microscope with a Plan Apochromat 63x objective/1.4 NA oil objective was used for 
super-resolution microscopy.  Images were acquired with the following scan parameters: a 
"frame" scan mode of 1024 x 1024 pixels with a 16 bit depth and a grating of 3 rotations. For 
imaging the mitochondria, 561 nm excitation was used and emission was collected with a BP 
570-620 nm filter. Fluorescence intensity was collected using a sCMOS pco.edge EMCCD 
camera with exposure time set to 100 ms.  
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2.10 Flow cytometry 
Cells were harvested and washed 2 times by adding HBSS, centrifuged at 2000 rpm for 5 
min and aliquoted 3 x 105 cells in FACS tubes. Cells were fixed using cold 4 % 
paraformaldehyde for 10 min, permeabilized using 0.3 Triton X-100 for 15 min at room 
temperature and blocked 30 min at room temperature with corresponding 5 % host serum. Cells 
were immunostained for an hour in 0.1 % Triton X-100, 1 % BSA at 4 °C using either NIK-
specific antibody (ab191591), pDRP S637 (4867S), or pDRP S616 (3455S). After three times 
wash with HBSS, cells were incubated in secondary antibody (AF488 or AF594, Invitrogen) for 
30 min in the dark and wash with HBSS. Finally, cells were resuspended in 300 μL HBSS and 
analyzed using BD LSR Fortessa™ X-20 cell analyzer (BD Biosciences, San Jose, CA). At least 
10,000 events were measured. Data were analyzed using Flow Jo V-X (Flowjo Llc, Ashland, 
OR). 
 
2.11 Quantification of mitochondrial number and size and tracking 
All Mito-RFP images were taken on a Nikon TI A1R inverted confocal microscope or 
Nikon Eclipse Ti microscope with similar contrast and at the same magnification. Each particle 
in individual cells was outlined and measured for mitochondrial number and average size 
utilizing particles analyzer in ImageJ (NIH) (Dagda et al., 2009). BT25 cells were plated on 8 
well chamber slides with a glass bottom and incubated with CellLight Mitochondria-RFP (Mito-
RFP) BacMam reagent (C10601).  After 18 hr, time-lapse imaging was performed every 10 s for 
5 min, and movies of mitochondria were acquired at a rate of 5.2 frames per second using a 
Nikon TI A1R inverted confocal microscope with 60x Plan-Apochromat lenses and Stage-top 
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incubator system. NIS Elements software (Nikon) with tracking module was used to track and 
analyze movement of single mitochondria. 
 
2.12 Subcellular fractionation 
Cultured cells were washed twice with ice-cold PBS and scraped in 2 ml of ice-cold PBS. 
After removing supernatants following centrifugation at 800 xg for 5 min, pellets were 
resuspended and homogenized in homogenization buffer (10 mM HEPES-KOH, pH 7.5, 0.25 M 
sucrose) by passing a 27-gauge needle 10 times. Post-nuclear supernatants were collected by 
centrifugation at 1,000 xg for 10 min and then, heavy membrane fraction was separated from the 
resultant supernatant by centrifugation at 8,000 xg for 10 min at 4 ˚C. The pellets of heavy 
membrane fraction as mitochondria enriched fraction were washed with buffer and solubilized in 
100 μl of solubilization buffer (50 mM Tris-HCI [pH 8.8], 5 mM EDTA, 1 % SDS). The 
remaining supernatants as cytosol fraction were centrifuged again at 16,000 xg for 10 min at 4 ˚C 
to remove any remain membrane fraction. 
 
2.13 Immunoblot 
Cells were lysed in RIPA lysis buffer (Pierce, Rockford, 89900) with 
protease/phosphatase inhibitor cocktail (Thermo Scientific, 78440). Equal amounts of protein 
were mixed with NuPage 4X LDS sample buffer (Invitrogen, NP0008) containing reducing 
agent and denatured at 100 ˚C for 7 min. Proteins were separated on 8 % - 12 % SDS-PAGE and 
transferred to nitrocellulose membranes (Bio-Rad, #162-0115). The membranes were blocked for 
1 h with 5 % non-fat dry milk in 0.1 % Tween-20/TBS (TBST) or Odyssey blocking buffer (LI-
COR Biosciences, 927-40000) and incubated with primary antibodies diluted in blocking buffer 
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at 4 °C overnight. After washing in TBST, membranes were incubated with goat anti-rabbit 
IRDye800CW (LI-COR Biosciences, 926-32211), goat anti-mouse IRDye680 (LI-COR 
Biosciences, 926-68070) or goat anti-rabbit HRP conjugate (Thermo Scientific, 31460) diluted in 
blocking buffer and incubated for 1 hour at room temperature. The blots were washed with 
TBST and developed using Chemiluminescent HRP Substrate (EMD Millipore, WBKLS0100) 
for detection of HRP or an Odyssey Infrared Imaging system (LI-COR Biosciences) for 
detection of IRDye fluorescent dyes. 
 
2.14 Immunoprecipitation 
Cells were lysed with in RIPA lysis buffer with Protease/Phosphatase Inhibitor Cocktail. 
500 μg of proteins from each sample were incubated with 5 μg of Drp1 antibody (Abcam, 
56788), Tim50 antibody (Santa Cruz, 393678), PGAM5 antibody (Abcam, 126534), Miro1 
antibody (Abcam, 211363), control mouse IgG (Santa Cruz, 2025) or Rabbit IgG (Cell Signaling 
Technology, 2729) covalently bound to protein A magnetic beads (Life Technologies, 10001D) 
for 18 hr at 4 °C on a rotator. Beads were collected using a magnetic stand and washed four 
times with ice-cold RIPA buffer followed by boiling in 1 × LDS sample buffer containing 
reducing agent for 7 min at 100 ˚C. Proteins were separated on 8 % ~ 12 % SDS-PAGE followed 
by western blot using appropriate antibodies. 
 
2.15 RNA isolation, cDNA synthesis, and quantitative-RT-PCR 
Total RNA was isolated from cells by Purelink™ RNA Mini Kit (Life Technologies). 
cDNA was synthesized from 1 μg total RNA using iScript reverse transcription supermix (Bio-
Rad, Hercules, CA) following the manufacturer's protocol. Quantitative RT-PCR was performed 
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using iTaq Universal SYBR Green Supermix (Bio-Rad) with StepOnePlus Real-Time PCR 
System (Applied Biosystems, Foster City, CA). The following primers were used: human NIK, 
5’-CTAGTGCATGCTCTGCAAGG-3’ and 5’-TGAGTTTCTCAGTGAGCAGGA-3’; mouse 
NIK, 5’-CCAGAATCGTCCCTCTCTAT-3’ and 5’-GACAGCCCATTTGCTTTATG-3’; mouse 
MMP9 5’-GATC CCC AGA GCG TCATTC-3’ and 5’-CCACC TTG TTC ACC TCA TTTTG-
3’; human GAPDH, 5’-GAAGGTGAAGGTCGGAGTC-3’ and 5’-
GAAGATGGTGATGGGATTTC-3’; mouse GAPDH, 5’-CTTTGTCAAGCTCATTTCCTGG-
3’ and 5’-TCTTGCTCAGTGTCCTTGC-3’. Expression of mRNA was normalized to either 
GAPDH expression levels. All experiments were performed at least three times with three 
replicates per sample. 
 
2.16 Mito-PAGFP fusion assay 
BT25 cells were plated on µ-Slide 8 well chamber slides with a glass bottom (ibidi) and 
cotransfected with mito-PAGFP (Addgene, #23348) and pDsRed2-Mito (Addgene, #55838). 
After 24 hr, cells were imaged on a Nikon TI A1R inverted confocal microscope with 100x Plan-
Apochromat lenses and Stage-top incubator system including heated stage and carbon dioxide 
chamber.  A region of interest (ROI) of approximately 4 μm-wide was selected and activated by 
a short pulse of 405 nm laser.  Imaging of post-activation was obtained immediately by the 488 
nm laser and subsequent images were taken every 15 min for a total of 45 min.  The dilution of 
mito-PAGFP fluorescence in time-lapse images was analyzed by measuring the pixel intensities 
using ImageJ (NIH). 
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2.17 ROS assay 
Cellular Reactive oxygen species (ROS) levels were assayed using the CellROX Green 
reagent (Thermo Fisher, C10444) diluted 1:500 for 30 minutes at 37 °C. At least 10,000 events 
were measured and data was analyzed using Flow Jo V-X (Flowjo Llc, Ashland, OR). 
 
2.18 Oxygen Consumption Assay 
1.5 x 104 cells were seeded in triplicate in black clear bottom 96 well plates (Corning, 
CLS3603) in 150 μL NSC media containing 10% FBS and were allowed to adhere at 37 °C 
overnight.  10 μL of Mito-ID Extracellular O2 Sensor probe (ENZ-51045-K100) from Enzo Life 
Sciences (Farmingdale, NY) was reconstituted in PBS was added to each well and 2 drops of 
Mito-ID HS Oil was added to seal each well.  The cells were then immediately analyzed with a 
Cytation 3 plate reader (Biotek, Winooski, VT). Reads were taken every 20 minutes over the 
course of 7 hours.  All graphs and statistical data were analyzed using GraphPad Prism 
(GraphPad Software Inc., San Diego, CA, USA). 
 
2.19 Monitoring mitochondrial constriction and division 
BT25 cells and COS-7 cells expressing GFP-NIK, mCherry-Drp1 (Addgene, #49152), 
and mito-BFP (Addgene, #49151) were plated on µ-Slide 8 well chamber slides with a glass 
bottom (ibidi). After 18 hr, time-lapse images were acquired every 5 s for 2 min on Nikon TI 
A1R inverted confocal microscope with 60x Plan-Apochromat lenses and Stage-top incubator 
system. The diffuse cytosolic images were threshold-adjusted by subtracting background signal 
in the cytosol. 
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2.20 In vitro kinase assay  
GST-Drp1518–736 (Kashatus et al., 2015) was expressed in E. coli BL21 and purified using 
glutathione-sepharose-4B (GE Healthcare, #17075601). The GST fusion protein eluted from the 
beads via glutathione (Sigma-Aldrich, G4251) was dialyzed against PBS. 500 ng GST-Drp1 was 
incubated with cell lysates of transfected 293T cells (NIK wild-type and NIKK429A/K430A) or HA-
NIK (wild-type and mutant K429A/K430A)-bound beads in 25 μl 1× Kinase Buffer (Cell 
Signaling Technology, 9802) and 20 μM ATP for 15 min at 37 °C. The kinase assay was 
terminated by the addition of LDS sample buffer containing reducing agent for 7 min at 100 ˚C 
and resolved by SDS-Page. 
 
2.21 Xenograft mouse models 
All animal experiments were done in compliance with IACUC, AAALAC and Texas 
A&M Health Science Center Biosafety guidelines using an IACUC-approved Animal Use 
(Protocol # 2015-0330). For orthotopic tumor inoculations, cells were labeled using a DiD 
Cytoplasmic Membrane dye (Biotium, abs/ em=644/665).  5x105 cells in 3 µl PBS medium were 
injected into the right striatum of 4 - 6 week old CD-1 nude mice. Tumor formation was imaged 
using an In Vivo FX Imaging System (Carestream, Rochester, NY). Injections were done using 3 
- 4 animals for each cell type. 
 
2.22 In situ proximity ligation assay   
The in situ Proximity ligation assay (PLA) was performed according to the 
manufacturer's instructions, using the Duolink PLA reagents (Sigma-Aldrich, Louis, MO, USA). 
BT25 control and BT25-sgNIK cells were fixed in 4 % paraformaldehyde for 20 min and 
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permeabilized for 20 minutes with 0.3 % Triton X-100 followed by blocking at room 
temperature for 30 min. Cells were incubated with primary antibodies against NIK (Abcam, 
ab191591), Drp1 (Abcam, ab56788), PGAM5 antibody (Abcam, 126534) or control mouse IgG 
(Santa Cruz, 2025) for 18 hours at 4°C, followed by washing and incubation with the Duolink®  
In Situ PLA®  Probe Anti-Rabbit PLUS and Anti-Mouse MINUS (Sigma-Aldrich, DUO92002, 
DUO92004). After ligation and amplification using DUO92008 Duolink®  In Situ Detection 
Reagents Red (Sigma-Aldrich, DUO92008), the cells were counterstained with DAPI and 
Tom20-AF647 (Abcam, ab205487) and red PLA signals were visualized under a TI A1R 
inverted confocal microscope (Nikon). 
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CHAPTER III  
NIK REGULATES MITOCHONDRIAL DYNAMICS TO PROMOTE CELL INVASION 
INDEPENDENTLY OF IKK/NF-ΚB 
 
3.1 Summary 
Although the role of NIK in immunity is well established, its relevance in cancer is just 
emerging. Here we describe novel functions for NIK in regulating mitochondrial dynamics and 
motility to promote cell invasion. We show that NIK is localized to mitochondria in cancer cell 
lines, ex vivo tumor tissue, and MEFs. NIK recruits Drp1 to promote mitochondrial fission and 
subcellular distribution to the leading edge of migrating cells. Consistent with a role for NIK in 
regulating mitochondrial dynamics, we demonstrate that Drp1 is required for NIK-dependent, 
cytokine-induced invasion. Importantly, using MEFs, we demonstrate that the established 
downstream mediators of NIK signaling, IκB kinase α/β (IKK α/β) and NF-κB, are not required 
for NIK to regulate cell invasion, Drp1 mitochondrial localization, or mitochondrial fission. 
Taken together, these findings reveal a previously unknown pool of NIK protein that is localized 
to mitochondria in cancer cells and regulates mitochondrial dynamics, motility and cell invasion 
independently of the IKK/NF-κB signaling cascade. 
 
3.2 Introduction 
NIK, the central kinase activating the non-canonical NF-κB pathway, has been shown to  
                                                 

Part of this chapter is reprinted with permission from “NIK/MAP3K14 Regulates Mitochondrial Dynamics and 
Trafficking to Promote Cell Invasion.” By Jung JU, Ravi S, Lee DW, McFadden K, Kamradt ML, Toussaint LG, 
Sitcheran R, 2016. Current Biology, 26, 3288-3302, Copyright 2016 by Elsevier Ltd. 
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contribute to tumorigenesis in several cancers through regulating cell proliferation and survival 
(Thu and Richmond, 2010; Xia et al., 2014). However, the molecular mechanisms by which NIK 
stimulates tumor growth have not been fully elucidated. Our previous work demonstrated that 
non-canonical NF-κB signaling is significantly increased in highly invasive glioma tumor lines, 
compared to less invasive glioma lines (Cherry et al., 2015; Lee et al., 2013). More recently, we 
have shown that the ability of NIK to promote glioma invasiveness is associated with cell shape 
changes, including formation of invadopodia pseudopodial membrane protrusions and cell size 
(Duran et al., 2016). Why is cell size shown to positively correlate with the expression of NIK? 
Cell size correlates with the proliferative potential and metabolic demands of cancer cells (Dolfi 
et al., 2013). Large cell size correlates with mitochondria abundance that is associated with 
cancer progression (Grupp et al., 2013; Yamamoto et al., 2014). Interestingly, tumor cell 
migration and invasion have been linked to regulation of mitochondrial dynamics, and more 
specifically, to alterations in the balance between mitochondrial fission and fusion (Caino and 
Altieri, 2015; Desai et al., 2013; Ferreira-da-Silva et al., 2015; Zhao et al., 2013). Indeed, cancer 
cells often exhibit a fragmented mitochondrial phenotype (Arismendi-Morillo, 2009; Inoue-
Yamauchi and Oda, 2012; Rehman et al., 2012). During cancer cell migration, mitochondria are 
redistributed to the leading edge containing invadopodia, a subcellular region requiring high 
energy due to extensive cytoskeletal and focal adhesion remodeling during cell movement 
(Caino and Altieri, 2015). Consistent with these observations, the mitochondria-associated 
fission protein Drp1 has been shown to promote tumor migration, invasion and pathogenesis 
(Senft and Ronai, 2016). 
Regulation of NIK, a constitutively active kinase (Liu et al., 2012), occurs primarily at 
the post-translational level. In unstimulated cells, NIK is rendered inactive through its 
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association with a TRAF-cIAP complex that catalyzes its ubiquitination and continuous 
proteasome-dependent degradation in the cytosol (Sun, 2012). Activation of NIK is achieved 
through disassembly of the degradation complex, resulting in stabilization and accumulation of 
NIK protein (Sun, 2010). Once stabilized, NIK phosphorylates and activates IKK, which in 
turn phosphorylates p100, triggering proteolytic processing to p52 and nuclear translocation of 
p52-RelB non-canonical NF-κB transcription factors (Razani et al., 2011; Sun, 2010). The 
predominant, physiological function of NIK is to activate IKK and non-canonical NF-κB 
signaling, but NIK can also induce IKK-dependent, canonical NF-κB signaling, particularly 
when NIK is overexpressed, or aberrantly stabilized (Odqvist et al., 2013; Oeckinghaus et al., 
2011; Ramakrishnan et al., 2004). Functions for IKK-independent NIK signaling have not been 
described to date. 
Generally, subcellular localization of a protein can provide crucial information about its 
function. While NIK is known to be present mainly in the cytoplasm and quickly translocates 
into the nucleus, in this study, we identified novel protein pools of NIK localized at the 
mitochondria that functions independently of IKK/ NF-κB to promote mitochondrial 
fragmentation and tumor cell invasion. 
 
3.3 Results 
3.3.1 NIK is localized to mitochondria in cancer cells and promotes invasion 
Proteomics analysis has revealed an enrichment of mitochondrial proteins in invadopodia 
(Attanasio et al., 2011), and recent cell-biological studies have shown a re-distribution of 
mitochondria to the leading edge of cells during migration (Desai et al., 2013). These 
observations suggest that mitochondria move to distal cell protrusions and sites of active cell 
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invasion. In light of our recent findings that NIK promotes invasion of glioma cells and induces 
cell shape changes, including pseudopodia/invadopodia formation (Duran et al., 2016), we 
sought to determine whether NIK plays a role in these processes using a highly invasive (BT25) 
and a minimally invasive (BT114) glioma cell line derived from human glioma patients that 
express high and low levels of NIK, respectively (Fig. 6) (Cherry et al., 2015). We first 
investigated NIK’s role in BT25 cells and employed small guide (sg) RNAs in combination with 
the CrispR/Cas9 gene editing system in BT25 cells to generate tumor cells lacking a functional 
NIK gene (BT25-sgNIK) (Duran et al., 2016). Loss of NIK significantly attenuates invasion in 
three-dimensional collagen matrices compared with control cells, and invasion was restored with 
expression of the highly conserved, murine NIK (BT25-sgNIK+rescue) (Fig. 7).  
To visualize mitochondria, we transfected BT25 control, BT25-sgNIK and BT25-
sgNIK+rescue cells with the mitochondrial marker CellLight Mitochondria-RFP (Mito-RFP) 
(Kilgore et al., 2013). Confocal fluorescence microscopy revealed that mitochondria extended 
throughout the cell body to sites distal from the nucleus (Fig. 8A). However, in the absence of 
NIK (BT25-sgNIK cells), Mito-RFP staining appeared collapsed within the perinuclear region of 
cell, which had minimal cytoplasmic processes (Fig. 8B), while expression of murine NIK in 
NIK knockout cells (BT25 sgNIK+rescue) restored distal mitochondrial extensions, similar to 
control (Fig. 8C). Interestingly, when we performed NIK immunostaining to confirm alterations 
in NIK expression, we observed a striking co-localization of NIK with Mito-RFP in untreated 
BT25 control cells (Fig. 8A and D). Minimal NIK immunostaining was observed in BT25-
sgNIK cells, demonstrating specificity of the antibody (Fig. 8B), and re-expression of murine 
NIK (BT25 sgNIK+rescue cells) restored NIK mitochondrial staining (Fig. 8C and D). For 
detection of endogenous NIK protein by immunoblot, cells were treated with TWEAK (to induce 
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NIK/non-canonical NF-κB signaling) (Cherry et al., 2015) and the proteasome inhibitor MG132 
(to stabilize NIK for more facile detection). NIK protein was present in both mitochondrial-
enriched (M) and cytosolic (C) cell fractions of TWEAK/MG132-treated BT25 control cells and 
BT25 sgNIK+rescue cells. (Fig. 9). However, while mitochondrial NIK was readily detected by 
immunostaining, cytosolic NIK was not detectable, suggesting that antibody epitope availability 
differs in the cytosolic and mitochondrial compartments. NIK protein was not detected by 
immunoblotting in either fraction from BT25-sgNIK cells, confirming NIK knockout, as well as 
antibody specificity (Fig. 9). 
Given the close association of mitochondria with other organelles, particularly the 
endoplasmic reticulum (ER), as well as a recent report describing localization of a small fraction 
of NIK to endosomes in endothelial cells (Jane-wit et al., 2015), we examined NIK subcellular 
localization in more detail in BT25 glioma cells. Triple-immunostaining experiments showed 
that NIK immunostaining overlapped extensively with mitochondrial protein CoxIV, but not the 
ER protein Calnexin (Fig. 10A). Consistent with this observation, NIK showed extensive co-
localization with the mitochondrial outer membrane protein Tom20 (Fig. 10B), but not the ER 
protein Sec61, or the endosomal protein Rab5 (Fig. 11A and B).  
We next confirmed NIK’s function in mitochondria using gain-of-function studies in 
BT114 glioma cells. Interestingly, BT114 control cells displayed a mitochondrial phenotype that 
resembled BT25-sgNIK cells, with a concentration of Mito-RFP signal in the perinuclear region 
(compare Fig.12A to Fig. 8B). Overexpression of human NIK (BT114-hNIK) robustly increased 
invasion, compared to BT114 control cells (Fig. 13A and B). Furthermore, BT114-hNIK cells 
exhibited increased Mito-RFP staining throughout distal regions of the cell (Fig.12B). Though 
much weaker than BT25 cells, NIK immunostaining signal similarly colocalized with Mito-RFP 
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in BT114 control cells (Fig.12A). We were unable to detect any NIK in untreated BT114 cells 
(without TWEAK/MG132) by immunoblotting (Fig.12D). However, ectopically expressed NIK 
protein was observed in both mitochondrial and cytosolic fractions of BT114-hNIK cells 
(Fig.12D). 
To test whether mitochondrial localization of NIK, as well as its effect on mitochondrial 
intracellular distribution, was restricted to glioma cells, we performed immunostaining and 
invasion assays in MDA-MB231 breast cancer cells and Panc1 pancreatic cancer cells. As with 
glioma cell lines, we observed co-localization of NIK and Mito-RFP in both MDA-MB231 and 
Panc1 cells (Fig. 14A and 15A; top panels), and NIK immunostaining was lost in CrispR-Cas9 
mediated NIK knockout cells (Fig. 14A and 15A; lower panels), similar to BT25 knockout cells. 
Moreover, loss of NIK in MDA-MB231-sgNIK and Panc1-sgNIK cells resulted in condensed, 
perinuclear mito-RFP staining and significantly diminished invasive potential (Fig. 14 and 15). 
Together, these data identify a previously unknown pool of NIK protein that localizes to 
mitochondria in several different cancer cells and demonstrate a strong correlation between 
mitochondrial NIK expression and cell invasion. 
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Figure 6. Analysis of NIK protein expression and invasive potential in BT25 and BT114 cells. (A). Flow 
cytometry analysis was performed on fixed, permeabilized cells using NIK antibody and anti-rabbit AF-488. Results 
demonstrate that NIK is more highly expressed in BT25 cells compared with BT114 cells. Mean Fluorescence 
Intensity (MFI) of FITC signal is indicated. (B) Equal numbers (40,000 cells) of BT25 and BT114 cells were 
allowed to invade three-dimensional collagen matrices for 48 hours. Cells were fixes, stained and invading cells 
were counted from at least 3 random 10X fields from each replicate sample (n=3). Representative data from one 
experiment is shown (n>6). Results demonstrate that BT25 cells are significantly more invasive compared with 
BT114 cells. Statistics *** p<0.001, unpaired t-test. 
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Figure 7. Loss of NIK leads to decreased invasion potential in glioma cells. (A) Quantitative RT-PCR (qPCR) 
analysis of human and mouse NIK expression in human glioma cells: BT25 control, BT25-sgNIK and BT25-sgNIK 
cells expressing mouse NIK (sgNIK+rescue). For this and all subsequent experiments, representative data from at 
least three independent experiments are shown.  Graph shows mean values ± SD (n=3). Different letters indicate 
statistically significant differences: for A vs. B, p<0.001; for A/B vs. C, p<0.0001. (B) NIK expression correlates 
with invasive potential in three-dimensional collagen invasion assays. Relative invasion reflects numbers of 
invading cells normalized to control and data are represented as mean ± SD. ** p<0.001 for sgNIK vs. control and 
sgNIK vs. sgNIK+rescue, one-way ANOVA. 
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Figure 8. NIK is localized to mitochondria in glioma cells. (A) Immunofluorescence images of BT25 control, (B) 
BT25-sgNIK and (C) BT25-sgNIK+rescue cells transfected with Mito-RFP (red) and immunostained for NIK 
(green), and DAPI (blue). Images marked with white squares are amplified and shown in the bottom. Scale bar, 10 
μm. (D Bar graph showing Manders’ coefficients (fraction of NIK in co-localization with Mito-RFP) for co-
localization of NIK and mitochondria (C - E). Data are mean ± SD (n=12). ** p<0.01 for sgNIK vs. control and 
sgNIK vs. sgNIK+rescue, one-way ANOVA. 
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Figure 9. NIK protein is enriched in both mitochondrial and cytosolic fractions. Immunoblot analysis of 
mitochondrial-enriched (M) and cytosolic (C) fractions prepared from BT25 control, BT25-sgNIK and BT25-
sgNIK+rescue cells pretreated with TWEAK (10 ng/ml) and MG132 (5 μM) to stabilize NIK for facile detection and 
to confirm loss of protein in sgNIK cells. Four times the volume equivalent of mitochondrial-enriched fraction 
versus cytosol fraction was loaded (mitochondrial-enriched/cytosol = 4:1). Blots were probed with indicated 
antibodies. 
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Figure 10. NIK co-localization with specific mitochondrial markers in glioma cells. (A) Representative confocal 
immunofluorescence images of BT25 cells sequentially triple-stained with antibodies specific for mitochondrial 
marker CoxIV (red; AF564), endoplasmic reticulum marker calnexin (red; AF647) and polyclonal NIK (green; 
Abcam ab7204). NIK-specific antibody was pre-labeled with AF488. Left panel shows merged overlay (yellow-
orange) of NIK (green) and CoxIV (red). Right panel shows the same cell with merged overlay of NIK (green) and 
calnexin (pseudo-colored red). Scale bar, 10 µm. (B) Representative confocal immunofluorescence images of BT25 
glioma cells immunostained for NIK (green; Abcam ab191591) and pre-labeled antibody specific for Tom20-AF647 
(pseudo-colored red, upper panels). Images marked with white squares are amplified and shown in the bottom. Scale 
bar, 10 µm.   
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Figure 11. NIK has not signnificant co-localization with markers for the ER and endosome in glioma cells. (A) 
Representative confocal immunofluorescence images of BT25 glioma cells immunostained for NIK (AF564, 
pseudo-colored green) and pre-labeled antibody specific for Sec61A-AF488 (pseudo-colored red), and DAPI (blue). 
Images marked with white squares are amplified and shown in the bottom. Scale bar, 10 µm. (B) Representative 
immunofluorescence confocal microscopy images of BT25 cells transfected with dsRed-Rab5 and then fixed and 
stained with an antibody specific to NIK (green). Images marked with white squares are amplified and shown in the 
bottom. Scale bar, 10 µm.  
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Figure 12. Ectopically overexpressed NIK is localized to mitochondria in glioma cells. (A) Representative 
confocal immunofluorescence images are shown of BT114 control and (B) BT114-hNIK cells transfected with 
Mito-RFP and then immunostained for NIK (green), and DAPI (blue). (C) Bar graph showing results from 
measurements of mean fluorescent intensity of NIK staining in BT114 control (A) and BT114-hNIK cells (B) 
normalized to control and represented as mean ± SEM (n=30). *** p<0.001, unpaired t-test. (D) Immunoblot 
analysis of cell fractions prepared from untreated BT114 control and BT114- hNIK using the indicated antibodies. 
(mitochondrial-enriched/cytosol = 4:1 in volume equivalents). 
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Figure 13. NIK overexpression enhances invasion of glioma cells. (A) qPCR analysis of NIK expression in 
BT114 control and BT114-hNIK cells. Data are represented as mean ± SD. **** p<0.0001, unpaired t-test (n=3).  
(B) Quantification of three-dimensional collagen invasion assays comparing BT114 control and BT114-hNIK cells. 
Data are represented as mean ± SEM. *** p<0.001, unpaired t-test (n=3). 
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Figure 14. NIK is localized to mitochondria of invasive breast cancer cells.  (A) MDA-MB231 control cells 
(upper panel) and MDA-MB231 NIK knockout cells (sgNIK, lower panel) were transfected with Mito-RFP and then 
stained for NIK (green) and DAPI (blue). Representative confocal immunofluorescence images are shown. (B) NIK 
promotes the invasive potential of breast and pancreatic cancer cells. Quantification of three-dimensional collagen 
invasion assays comparing MDA-MB231 control and MDA-MB231-sgNIK (left panel). Relative invasion reflects 
numbers of invading cells normalized to control from at least three independent experiments, each with n≥3 for each 
cell type. For MDA-MB231 control vs. sgNIK: **** p<0.0001, unpaired t-test.   
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Figure 15. NIK is localized to mitochondria of invasive pancreatic cancer cells.  (A) Panc1 control cells (upper 
panel) and Panc1 NIK knockout cells (sgNIK, lower panel) were transfected with Mito-RFP and then stained for 
NIK (green) and DAPI (blue). No NIK signal is observed in Panc1-sgNIK cells. (B) NIK promotes the invasive 
potential of breast and pancreatic cancer cells. Quantification of three-dimensional collagen invasion assays 
comparing Panc1 control and Panc1-sgNIK cells (right panel). Relative invasion reflects numbers of invading cells 
normalized to control from at least three independent experiments, each with n≥3 for each cell type.  For Panc1 
control vs. sgNIK: ***p<0.001, unpaired t-test. 
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3.3.2 NIK regulates mitochondrial subcellular localization and motility  
To analyze NIK’s role in mitochondria clustering in more detail, we quantified 
intracellular mitochondrial distribution in BT25, BT25-sgNIK and BT25-sgNIK+rescue cells. 
Fluorescence intensity plots demonstrated that mitochondria in BT25 control cells extended from 
the nucleus to the distal edge of cells (Fig. 16A and D). Mitochondria in cells lacking NIK 
extended less than half the distance of those organelles in control cells, and remained collapsed 
in the perinuclear region (Fig. 16B and D). As expected, NIK overexpression (BT25-
sgNIK+rescue cells) restored the presence of mitochondria from the nucleus to the distal edge, 
similar to control cells (Fig. 16C and D).  To determine whether the accumulation of perinuclear 
mitochondria was associated with decreased mitochondria motility during cell migration, we 
performed live cell imaging and particle-tracking analysis of Mito-RFP-labeled mitochondria 
(watch the video linked; BT25 control cell 
http://www.cell.com/cms/attachment/2118002281/2085729692/mmc2.mp4; BT25-sgNIK cell 
http://www.cell.com/cms/attachment/2118002281/2085729693/mmc3.mp4; BT25-
sgNIK+rescue cell http://www.cell.com/cms/attachment/2118002281/2085729694/mmc4.mp4). 
Results from these experiments revealed that the velocity and overall distance traveled by 
mitochondria was significantly compromised in BT25-sgNIK cells, and these defects were 
restored by re-expression of NIK (BT25-sgNIK+rescue cells; Fig. 17). Moreover, mitochondria 
in BT25 control and BT25-sgNIK+rescue cells exhibited predominantly anterograde movement 
and directional migration towards the cell periphery, whereas mitochondria in BT25-sgNIK cells 
exhibited seemingly random patterns of both anterograde and retrograde movement (Fig. 18). 
These data indicate that NIK regulates velocity and directional migration of mitochondria, 
resulting in subcellular distribution of mitochondria to the periphery of regions of the cells. 
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Figure 16. NIK regulates mitochondrial distribution.  Fluorescence intensity profile plot of BT25 control (A), 
BT25-sgNIK (B), and BT25-sgNIK+rescue cells (C). Graphs show the immunofluorescence intensity, expressed in 
arbitrary units (a.u.), of Mito-RFP (red), DAPI (blue) and Phalloidin (green) along the line arrow in lower images. 
Scale bar, 5 µm. (D) Bar graph shows quantification of distance from the nucleus to mitochondria. Data are 
represented as mean ± SD (n>10). ** p<0.01 for sgNIK vs. control and sgNIK vs. sgNIK+rescue, one-way 
ANOVA. 
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Figure 17. NIK regulates both velocity and run distance of mitochondria. Plot of run length (A) and velocity (B) 
of mobile mitochondria in the cells expressing Mito-RFP as supplementary material Movie S1. Data are represented 
as mean ± SD. of randomly selected mitochondria shown in different colors (n > 10 cells, respectively). 
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Figure 18. NIK influences direction of mitochondrial movement. (A) Vector paths of single mitochondria 
observed during live-cell imaging representing the tracks and (B) direction of mitochondria movement. The 
intersection point of X the Y axis is starting point of each mitochondria. 
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3.3.3 NIK regulates mitochondrial morphology through promoting fission 
We next performed superresolution-structured illumination microscopy (SR-SIM) of 
Mito-RFP-labeled BT25 cells. Results from these experiments demonstrated that mitochondria in 
BT25 control cells were fragmented and punctate, forming elongated tracks throughout the 
cytoplasm that extended towards the cell periphery (Fig. 19A). In BT25-sgNIK cells, however, 
mitochondria were more tangled, fused and condensed within the perinuclear region (Fig. 19B), 
a phenotype that was reversed by mNIK overexpression (Fig. 19C). We also performed particle 
analysis of Mito-RFP staining using ImageJ, which revealed that while the number of 
mitochondria was significantly decreased in cells lacking NIK (BT25-sgNIK cells) compared to 
corresponding control cells, mitochondria size increased (Fig. 20). Conversely, NIK 
overexpression (BT114-hNIK cells) was associated with increased number and decreased size of 
mitochondria (Fig. 21).  
Lastly, to determine whether the increased mitochondrial size in BT25-sgNIK cells 
reflected altered mitochondrial dynamics, we examined mitochondrial fusion in live cells using a 
mitochondrial matrix-targeted photoactivatable green fluorescent protein (mito-PAGFP)-based 
assay (Karbowski et al., 2014). Fluorescence intensity in specific regions of interest (ROIs) had 
very similar rates of dissipation in BT25 control and BT25-sgNIK cells (Fig. 22), demonstrating 
that mitochondrial fusion is not significantly impaired in the absence of NIK. Together, these 
results strongly suggest a role for NIK in promoting mitochondrial fission leads to mitochondrial 
dynamics. 
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Figure 19. Super-resolution microscopy of mitochondrial morphology.  (A) Super-resolution structured 
illumination microscopy (SR-SIM) was performed with the following cells expressing Mito-RFP: BT25 control, (B) 
BT25-sgNIK, and (C) BT25-sgNIK+rescue. Images marked with white squares are magnified and shown in the 
bottom. Scale bar, 10 µm. 
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Figure 20. Loss of NIK results in a hyperfused mitochondrial network. Mitochondrial number and size in BT25 
control, BT25-sgNIK, and BT25-sgNIK+rescue were quantified using the Analyze Particles function in ImageJ 
software. Data are represented as mean ± SD. ** p<0.01 for sgNIK vs. control and sgNIK vs. sgNIK+rescue, one-
way ANOVA (n > 100, respectively). 
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Figure 21. Overexpression NIK leads to increase in mitochondrial fragmentation. Mitochondrial number and 
size in BT114 control and BT114-hNIK were quantified using the Analyze Particles function in ImageJ software 
(±SEM **p<0.01; *p<0.05, using unpaired Student’s t-test, N=47 and 27 cells, respectively). 
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Figure 22. Fusion analysis in BT25 glioma cells.  (A) Fusion analysis in BT25 cells. BT25 control, BT25-sgNIK, 
and BT25-sgNIK+rescue cells were co-transfected with mito-PAGFP (green) and pDsRed2-Mito (red). The mito-
PAGFP was photoactivated with a 405 nm laser, and images were acquired with 15 min intervals for 45 min after 
activation. Percentage of GFP fluorescence intensity of a regions of interest (ROI) at different time points was 
normalized by the highest intensity. Representative images from at least three independent experiments are 
visualized as grayscale. Same trends were consistently observed in each experiment. Scale bar, 10 µm. Inserts are 
magnifications of the boxed regions. (B) Selected mitochondrial regions were analyzed for their PAGFP 
fluorescence intensity (mean ± SD, one-way ANOVA, N= 6 cells, respectively). There was no significant difference 
between the dilution rates of BT25 control, BT25-sgNIK, and BT25-sgNIK+rescue cells. 
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3.3.4 NIK recruits Drp1 to mitochondria and influences its activity 
The GTPase Drp1 is a cytosolic factor that is recruited to the mitochondria where it 
promotes mitochondrial fission (Smirnova et al., 2001). To investigate whether Drp1 expression 
and subcellular localization is regulated by NIK, we performed immunostaining experiments. 
Drp1 broadly observed in the cytosol as a punctate signal and also colocalized with Mito-RFP in 
BT25 control cells (Fig. 23A). Intriguingly, Drp1 association with Mito-RFP was significantly 
diminished in BT25-sgNIK cells, but was restored in BT25-sgNIK+rescue cells (Fig. 23B, C, 
and D). No Drp1 staining was observed in BT25 cells expressing small guide RNAs for CrispR-
Cas9 mediated knockout of Drp1 (BT25-sgDrp1 cells), verifying antibody specificity (Fig. 24A 
and B). A second Drp1 antibody, whose specificity was also verified, primarily recognized 
mitochondrial but not cytosolic Drp1, and also showed loss of Drp1 mitochondrial co-
localization in BT25sgNIK cells (Fig. 24C). 
Biochemical fractionation and immunoblot analyses confirmed that Drp1 was present in 
both cytosolic and mitochondria-enriched fractions of BT25 control cells (Fig. 25). In contrast, 
BT25-sgNIK cells exhibited diminished Drp1 protein levels specifically in the mitochondrial-
enriched fraction (Fig. 25). Again, levels of mitochondrial Drp1 were restored in BT25-
sgNIK+rescue cells (Fig. 25), demonstrating that the observed effects in BT25-sgNIK cells are 
mediated by NIK. The expression of other mitochondrial dynamic regulators, including Mff, 
Fis1, Opa1, and Mfn1/2 were not significantly altered in BT25-sgNIK cells compare to the 
control cells, whereas expression levels of the proteins in BT114-hNIK cells were slightly raised 
(Fig. 26A and B). Additionally, Tom20 levels were not affected in mitochondrial fractions of 
BT25-sgNIK cells (Fig. 25). These results suggest that mitochondria membrane protein topology 
is not grossly altered, and that NIK specifically regulates Drp1 mitochondrial localization.  
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Drp1 is regulated by posttranslational modification, including phosphorylation at serine 
residues 616 (Drp1-P616) and 637 (Drp1-P637), which enhances and inhibit its fission-
promoting activity, respectively (Chang and Blackstone, 2007b; Taguchi et al., 2007). To 
investigate the potential regulation of Drp1 activity by NIK, we examined Drp1 phosphorylation 
in cells with altered NIK expression using flow cytometry. In BT25-sgNIK cells, Drp1-P616 
levels decreased along with a concomitant increase in Drp1-P637, when compared to BT25 
control cells (Fig. 27A and B), suggesting that NIK enhances the fission-promoting activity of 
Drp1. Similar to cells lacking Drp1, loss of NIK also exhibited differences in other mitochondrial 
functions, including a decrease in production of reactive oxygen species (ROS) and oxygen 
consumption (Fig.28 and 29). Taken together, these results indicate that NIK regulates Drp1 
mitochondrial recruitment and activity to promote mitochondrial fission. 
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Figure 23. Loss of NIK diminishes mitochondrial association of Drp1. (A) BT25 control (upper panel), (B) 
BT25-sgNIK (middle panel) and (C) sgNIK+rescue cells (lower panel) were transfected with Mito-RFP to visualize 
mitochondria (red) and then immunostained for Drp1 (green), and DAPI (blue). Areas within white squares are 
amplified and shown on the right. Scale bar, 10 µm. (D) Bar graph showing Manders’ coefficients for co-
localization of Drp1 and Mito-RFP (A - C). Data are mean ± SD (n>8). ** p<0.01 for sgNIK vs. control and sgNIK 
vs. sgNIK+rescue, one-way ANOVA. 
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Figure 24. Drp1 antibody validation and staining.   (A) BT25 control (upper panel), BT25-sgNIK (middle panel) 
and sgDrp1 (lower panel) cells were transfected with Mito-RFP to visualize mitochondria (red) and then 
immunostained with a Drp1 antibody against endogenous Drp1 (Abcam #56788; green), and DAPI (blue). Images 
marked with white squares are amplified and shown in the right. Scale bar, 10 µm. (B) Immunoblot analysis of 
whole cell lysates prepared from BT25 control and BT25-sgDrp1 cells were probed with Drp1 and β-actin-specific 
antibodies, as indicated. (C) BT25 control (upper panel) cells were transfected with Mito-RFP (red) and then 
immunostained with a Drp1 antibody (CST #8570; green), and DAPI (blue). sgDrp1 (lower panel) cells were 
immunostained with a Drp1 antibody against endogenous Drp1 (CST #8570; green), mitochondrial marker Tom20 
and DAPI (blue). Images marked with white squares are amplified and shown in the right. Scale bar, 10 µm. 
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Figure 25. NIK enhances Drp1 recruitment to mitochondria.  Immunoblot analysis of mitochondrial-enriched 
(M) and cytosolic (C) fractions prepared from BT25 control, BT25-sgNIK and BT25-sgNIK+rescue cells was 
performed with indicated antibodies. Results are representative of 5 separate experiments. Right bar graph shows 
quantification of the ratio of Drp1 in cytosolic and mitochondria-enriched fractions. Mean ± SD (n>4). ** p<0.01 
for sgNIK vs. control and sgNIK vs. sgNIK+rescue, NS: not significant, one-way ANOVA. 
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Figure 26. Expression of mitochondria membrane proteins in cells with altered NIK expression. (A) 
Immunoblot analysis of whole cell lysates prepared from untreated BT25 control and sgNIK cells for endogenous 
mitochondrial fission proteins: Drp1, Mff, and Fis1; mitochondrial fusion proteins: Opa1, Mfn-1, and Mfn-2. β-actin 
is often used as a loading control. (B) Immunoblot analysis of whole cell lysates prepared from untreated 
BT114control and hNIK cells for endogenous mitochondrial fission proteins: Drp1, Mff, and Fis1; mitochondrial 
fusion proteins: Opa1, Mfn-1, and Mfn-2. β-actin is often used as a loading control. 
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Figure 27. NIK affects phosphorylation of Drp1. Flow cytometric histogram measuring levels of (A) Drp1-PS616 
and (B) Drp1-PS637 in BT25 control (green), sgNIK (red). Isotype control (grey). Right bar graph shows mean 
fluorescence intensity (MFI) values for control and sgNIK cells. At least 10,000 events were analyzed. Data are 
represented as mean ± SEM. **** p<0.0001, unpaired t-test. 
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Figure 28. Loss of NIK decrease the production of ROS. Cellular reactive oxygen species (ROS) was analyzed 
using CellRox reagent and performing flow cytometry in live cells BT25 control (green), sgNIK (red) and sgDrp1 
(blue) treated with Cell Rox reagent. At least 10,000 events were analyzed. Right bar graph shows mean 
fluorescence intensity (MFI) values from CellRox assy in (A). **** indicates significance of mean ± SEM p<.0001 
as analyzed by a one-way ANOVA. 
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Figure 29. Loss of NIK reduces oxygen consumption. Time course analysis of the change in extracellular O2 
consumption using a Mito-ID kit (ENZO life sciences). Higher fluorescence intensity indicates increased O2 
consumption. Reads were taken every 20 minutes over the course of 7 hours. Right bar graph shows fold change in 
total extracellular O2 consumption over 7 hours. Data are represented as mean ± SD ** p<0.01 (n=3) as analyzed by 
a one-way ANOVA. NS: not significant. 
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3.3.5 Drp1 interacts with NIK, but not IKK. 
To examine the distribution of NIK and Drp1 within mitochondria, we performed co-
immunostaining experiments in BT25 glioma cells. Drp1 immunoreactivity colocalized with that 
of NIK (Fig. 30A), but did not significantly overlap with IKK, the primary direct downstream 
target of NIK (Fig. 30B and C). Similarly, we observed that NIK, but not IKK, colocalized with 
Drp1 in patient-derived ex vivo glioma tissue (Fig. 31A and B). These data show that 
mitochondrial localization of NIK is an intrinsic property of primary human cancer cells, and not 
simply a phenotype observed in cancer cell lines in vitro. To determine whether the co-
localization of Drp1 and NIK immunostaining reflected a direct interaction, we performed 
immunoprecipitation experiments for Drp1 in BT114 control and BT114-NIK overexpressing 
cell. Results from these experiments indeed showed that Drp1 exists in a complex with NIK (Fig. 
32). However, the Drp1 does not interact with IKK, which is widely known as a NIK-binding 
protein for activating non-canonical NF-κB pathway. Additionally, NIK does not bind to other 
Drp1-related mitochondrial dynamic regulators including phosphoglycerate mutase family 
member 5 (PGAM5) (Xu et al., 2015) and mitochondrial Rho GTPase 1 (Miro1) (Saotome et al., 
2008) as well as a negative control, inner mitochondrial protein Tim50 (Tim 50) (Fig. 33). Thus, 
these data have suggested the existence of physical interaction between NIK and Drp1 in glioma 
cells. 
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Figure 30. Drp1 colocalized with NIK but not IKKα in glioma cells.  (A) BT25 control cells were 
immunostained for NIK (green), Drp1 (red), and DAPI (blue). Images marked with white squares are amplified and 
shown in the right. Scale bar, 10 µm. (B) BT25 control cells were immunostained for IKKα (green), Drp1 (red), and 
DAPI (blue). Images marked with white squares are amplified and shown in the right. Scale bar, 10 µm. (C) Bar 
graph showing Manders’ coefficients for co-localization of Drp1 and NIK or IKKα (A and B). Data are mean ± 
SEM (n=9). *** p<0.001, unpaired t-test. 
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Figure 31. Drp1 colocalized with NIK in human glioma patient tumor. (A) Human glioma patient tumor 
sections were stained for NIK (green) and Drp1 (red), and DAPI (blue); upper panel. Representative images from 1 
of 4 patient samples is shown. Images marked with white squares are amplified and shown in the right. Scale bar, 10 
µm. (B) Adjacent tumor sections were stained with IKKα (green), Drp1 (red), and DAPI (blue); lower panel. 
Images marked with white squares are amplified and shown in the right. Scale bar, 10 µm. 
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Figure 32. Drp1 interacts with NIK but not IKKα.  BT114 control (Con.) and BT114-hNIK cell (NIK OE) 
lysates were subjected to immunoprecipitation (IP) with control immunoglobulin G (IgG) or a Drp1 antibody against 
endogenous Drp1. The immunoprecipitates were analyzed by immunoblotting with the indicated antibodies. 
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Figure 33. Interaction between NIK and other Drp1-related mitochondrial dynamic regulators. BT114 control 
(Con.) and BT114-hNIK cell (NIK OE) lysates were subjected to immunoprecipitation (IP) with control IgG, (A) 
PGAM5, (B) Miro1or (C) Tim50 antibody. The immunoprecipitates were analyzed by immunoblotting with the 
indicated antibodies. 
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3.3.6 NIK requires Drp1 to promote TWEAK-induced invasion 
We have previously demonstrated that low, endogenous concentrations of the tumor 
inducing cytokine TWEAK (10 ng/ml) induces NIK expression and promotes NIK-dependent 
invasion (Cherry et al., 2015; Duran et al., 2016).  Indeed, TWEAK treatment increases invasion 
of BT25 cells to a similar extent as NIK overexpression, which is further potentiated by TWEAK 
(Fig. 34). As expected, loss of NIK (sgNIK) almost completely abrogates both basal and 
TWEAK-induced invasion (Fig. 34) (Duran et al., 2016), and this loss was rescued by NIK 
overexpression (sgNIK+NIK). To directly assess whether NIK acts through Drp1, we measured 
invasion of TWEAK treated BT25-sgDrp1 cells. Indeed, these cells showed strongly attenuated 
invasion, phenocopying BT25-sgNIK cells (Fig. 34). TWEAK was still able to increase invasion 
in these cells, but to significantly lower levels than in BT25 cells. More importantly, NIK 
overexpression in BT25-sgDrp1 had no effect on TWEAK-induced invasion (Fig. 34). 
Visualization and quantification of mito-RFP-labeled mitochondria revealed that while TWEAK 
increased the number of small, punctate mitochondria in BT25 control cells (Fig. 35A and C), it 
had no effect on BT25-sgDrp1 cells, which also exhibited collapsed, fused mitochondria, similar 
to BT25-sgNIK cells (Fig. 35B and C). Together, these results suggest that Drp1 activity and 
mitochondrial fission are important downstream mediators of NIK-dependent, TWEAK-induced 
cancer cell invasion. 
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Figure 34. NIK requires Drp1 to promote TWEAK-induced invasion.  Quantification of three-dimensional 
collagen invasion assays.  The indicated cells were allowed to invade three-dimensional collagen matrices in the 
absence or presence of the TWEAK (10 ng/ml). Data are represented as mean ± SD (n=3). Different letters represent 
statistically significant differences (A vs. B: ***p<0.001; A/B vs. D, A vs. B and C vs. E: ****p<0.0001;  D vs. E: 
*p<0.05; two-way ANOVA). 
 
 
 
 
 72 
 
 
 
 
 
 
 
Figure 35. TWEAK-induced mitochondria fragmentation requires Drp1.  Representative immunofluorescence 
images of (A) BT25 control and (B) BT25-sgDrp1 (right) cells in the absence or presence of the TWEAK (10 ng/ml) 
were transfected with Mito-RFP (red) and stained with DAPI (blue) and phalloidin (purple). Scale bar, 10 μm. (C) 
Mitochondrial number and size in BT25 control and BT25-sgDrp1 cells were quantified using the Analyze Particles 
function in ImageJ software. Data are represented as mean ± SD (n=14). Different letters represent statistically 
significant differences (D vs. F: *p<0.05; A vs. B and D vs. E: **p<0.01; A/B vs. C and E vs. F: ***p<0.001; one-
way ANOVA). 
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3.3.7 NIK enhances the invasive potential of MEFs in the absence of IKK/NF-κB signaling  
Lack of significant co-localization or interaction between IKK and Drp1 in glioma cells 
(Fig. 30B, 31B, and 32) led us to investigate whether NIK functions independently of IKK in the 
mitochondria. To do so, we took advantage of MEFs, which have the ability to undergo invasion 
in three-dimensional collagen matrices (Duran et al., 2016; Mierke et al., 2010), similar to 
glioma cells. Additionally, MEFs derived from IKK/ null mice (Li et al., 2000) (referred to as 
∆IKK-MEFs) provide a genetic tool to assess NIK function in the absence of IKK proteins and 
downstream NF-κB signaling. Immunofluorescence experiments in MEFs revealed that NIK 
broadly colocalized with Mito-RFP and Tom20 (Fig. 36A and 37A) and had minimal overlap 
with the ER protein Sec61 (Fig. 37B) in MEFs, similar to BT25 cells. As expected, MEFs in 
which NIK was knocked out using sgRNA-mediated CrispR/Cas9 genome editing (sgNIK 
MEFs) lacked any NIK protein, both by immunostaining and immunoblot analyses (Fig. 36A 
and B). Immunoblot experiments also demonstrated that NIK is present in mitochondrial-
enriched MEF cell fractions (Fig. 36B). Similar to glioma cells, little, if any, co-localization of 
IKK with Mito-RFP or NIK was observed in MEFs (Fig. 38A and B).  
Compared to WT MEFs, sgNIK MEFs exhibited substantially diminished invasion in 
collagen matrices and overexpression of human NIK (hNIK) in WT MEFs increased invasion 
(Fig. 39A and B). While ∆IKK-MEFs are somewhat less invasive than WT MEFs (Fig. 40A), 
additional deletion of NIK (sgNIK-∆IKK MEFs) further attenuated invasion in three-
dimensional collagen matrices (Fig. 40B). Overexpression of hNIK in ∆IKK MEFs (sgNIK-
∆IKK MEFs+rescue) increased invasion (Fig. 40C). Importantly, hNIK overexpression in ∆IKK-
MEFs did not activate downstream NF-κB signaling, assessed by the lack of any increase in 
p100 processing to p52, p65 (S536) phosphorylation or nuclear accumulation of p65, RelB or 
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p52 under basal or cytokine (TWEAK)-induced conditions (Fig. 41). Furthermore, ∆IKK MEFs 
overexpressing NIK did not exhibit increased expression of the NF-κB target gene MMP9 (Fig. 
42A and B) (Fukuyama et al., 2007; Li et al., 2009; Raychaudhuri et al., 2007). Together, these 
data clearly show that mitochondrial localization of NIK is a common event in both malignant 
and non-malignant cells. The NIK-dependent invasive potential of MEFs is uncoupled from 
IKK/NF-κB signaling.   
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Figure 36. NIK is localized to mitochondria in MEFs. (A) Representative immunofluorescence confocal images 
of WT and NIK knockout (sgNIK MEFs) that were transfected with Mito-RFP (red) to visualize mitochondria, then 
fixed and immunostained for NIK (green), DAPI (blue) and phalloidin (purple). Scale bar, 10 μm. (B) Immunoblot 
analysis of mitochondrial-enriched (M) and cytosolic (C) fractions prepared from WT and sgNIK MEFs pretreated 
with TWEAK (10 ng/ml) and MG132 (5 μM) to stabilize NIK for facile detection and to confirm loss of NIK in 
sgNIK MEFs. Blots were probed with indicated antibodies. (mitochondrial-enriched/cytosol = 4:1 in volume 
equivalents). 
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Figure 37. NIK co-localization with different organelle markers in MEFs. (A) Representative 
immunofluorescence confocal images of WT MEFs immunostaining for NIK (green), pre-conjugated Tom20-
AF647 (pseudo-colored red), and DAPI (blue). (B) WT MEFs were immunostained for NIK (pseudo-colored green), 
Sec61A-AF488 (pre-conjugated, pseudo-colored red), and DAPI (blue). Scale bar, 10 µm. 
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Figure 38. NIK's downstream target, IKKα does not colocalize with mitochondrial marker in MEFs. (A) WT 
MEFs were immunostained for NIK (green), IKKα (red), and DAPI (blue). (B) WT MEFs and (C) ∆IKK MEFs 
were immunostained for IKKα (green), Mito-RFP(red), and DAPI (blue). Images marked with white squares are 
amplified and shown in the right. Scale bar, 10 µm. 
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Figure 39. NIK regulates invasive potential in MEFs. (A) Immunoblot analysis of whole cell lysates prepared 
from WT MEFs (control for sgNIK) and sgNIK MEFs or (B) WT MEFs expressing control vector (control for 
overexpression) and hNIK were probed with NIK- and actin-specific antibodies, as indicated. Cells were pre-treated 
with TWEAK and MG132. The bar graph shows Quantification of three-dimensional collagen invasion assays 
comparing parental WT MEFs and sgNIK MEFs or WT MEFs-vector control and WT-hNIK. Relative invasion 
reflects numbers of invading cells normalized to each control from at least 3 independent experiments, each with 
n≥3 for each cell type. ** p<0.01; **** p<0.0001, unpaired t-test. 
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Figure 40. NIK increases the invasive potential of IKK-knockout MEFs. (A) (Left) Immunoblot analysis of 
whole cell lysates prepared from untreated WT MEFs and ∆IKK MEFs were probed with indicated antibodies.  
(Right) Quantification of three-dimensional collagen invasion assays comparing WT MEFs and ∆IKK MEFs. ** 
p<0.01 (n=3), unpaired t-test. (B) (Left) Immunoblot analysis of whole cell lysates prepared from ∆IKK MEFs 
(control) or NIK knockout (sgNIK-∆IKK MEFs) were probed with indicated antibodies. Cells were pre-treated with 
TWEAK and MG132. (Right) Quantification of three-dimensional collagen invasion assays comparing ∆IKK MEFs 
and sgNIK-∆IKK MEFs; **** p<0.0001(n=3), unpaired t-test. (C) (Left) Immunoblot analysis of whole cell lysates 
from untreated ∆IKK MEFs expressing vector (control) or hNIK was performed with indicated antibodies. (Right) 
Quantification of three-dimensional collagen invasion assays comparing ∆IKK MEFs expressing vector control or 
hNIK; ** p<0.01(n=3), unpaired t-test. 
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Figure 41. Overexpression of NIK in ∆IKK MEFs does not affect downstream NF-κB. Western blot analysis of 
cytosolic and nuclear fractions isolated from ∆IKK MEFs expressing vector (control) or hNIK and treated with 
TWEAK (10ng/ml) to induce NF-κB signaling. Blots were probed with the indicated antibodies.  
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Figure 42. Overexpression of NIK in ∆IKK MEFs does not affect expression of the NF-κB target gene. (A) 
Quantitative RT-PCR (qPCR) analysis of MMP9 expression in untreated WT MEFs and ∆IKK MEFs expressing 
vector (control) or hNIK. **** p<0.0001 (n=3), unpaired t-test, NS: not significant. 
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3.3.8 NIK regulates mitochondrial morphology by recruiting Drp1 independently of 
IKK/NF-κB 
To analyze mitochondrial morphology in MEFs, fluorescence microscopy was used to 
examine the morphology of mitochondria in ∆IKK MEFs, sgNIK-∆IKK MEFs, ∆IKK 
MEFs+vector and ∆IKK MEFs+hNIK cells expressing a mito-RFP. The fluorescent images 
showed that loss of NIK in WT and ∆IKK MEFs resulted in collapsed, perinuclear mito-RFP 
staining (Fig. 43A and 44A), similar to BT25-sgNIK, Panc1-sgNIK and MDA-MB231-sgNIK 
cells (Fig. 8B, 14A, and 15A). Moreover, overexpression of NIK in both WT and ∆IKK MEFs 
increased the appearance of punctate mitochondria dispersed throughout the cytoplasm (Fig. 43A 
and 44B). Particle analysis of Mito-RFP staining using ImageJ revealed that although the number 
of mitochondria was significantly decreased in ∆IKK-MEFs compared to corresponding WT 
MEFs, mitochondria size was increased (Fig. 43B). Conversely, NIK overexpression in ∆IKK-
MEFs (∆IKK+hNIK) was associated with increased number and decreased size of mitochondria 
(Fig. 43B). Similar to BT25 cells, ∆IKK MEFs also exhibited co-localization of Drp1 with Mito-
RFP, which was significantly diminished in sgNIK-∆IKK MEFs (Fig. 45). Biochemical 
fractionation and immunoblot analyses confirmed loss of Drp1 protein specifically in the 
mitochondrial-enriched fraction of sgNIK-∆IKK MEFs (Fig. 46). Together, these findings 
demonstrate that NIK regulates mitochondrial fission by increasing the mitochondrial 
recruitment of Drp1 independently of IKK/NF-κB. 
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Figure 43. NIK regulates mitochondrial morphology of MEFs in the absence of IKK/NF-κB signaling. (A) 
Representative immunofluorescence confocal images of ∆IKK MEFs, ∆IKK MEFs+vector, sgNIK-∆IKK MEFs and 
∆IKK MEFs+hNIK that were transfected with Mito-RFP (grayscale) to visualize mitochondria. Images marked with 
white squares are amplified and shown in the right. Scale bar, 10 μm. (B) Mitochondrial number and size in WT 
MEFs, ∆IKK MEFs, ∆IKK MEFs+hNIK and sgNIK-∆IKK MEFs were quantified using the Analyze Particles 
function in ImageJ software. Data are represented as mean ± SD (n>16). *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001; one-way ANOVA). 
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Figure 44. NIK promotes mitochondrial fragmentation in MEFs. (A) Representative immunofluorescence 
confocal images of WT MEFs and sgNIK MEFs and (B) WT MEFs and WT-hNIK that were transfected with Mito-
RFP (grayscale) to visualize mitochondria. Images marked with white squares are amplified and shown in the right. 
Scale bar, 10 μm. 
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Figure 45. NIK contributes mitochondrial localization of Drp1 in IKK-knockout MEFs. ∆IKK MEFs and 
sgNIK-∆IKK MEFs were transfected with Mito-RFP to visualize mitochondria (red) and immunostained for Drp1 
(green), and DAPI (blue). Images marked with white squares are amplified and shown in the right. Scale bar, 10 μm. 
Right bar graph shows Manders’ coefficients (fraction of Drp1 in co-localization with Mito-RFP) for co-localization 
of Drp1 and mitochondria. Data are mean ± SEM (n>14). ** p<0.01, unpaired t-test. 
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Figure 46. NIK enhances Drp1 recruitment to mitochondria in IKK-knockout MEFs. Immunoblot analysis of 
mitochondria-enriched (M) and cytosolic (C) fractions from ∆IKK MEFs and sgNIK-∆IKK MEFs was performed 
with the indicated antibodies.  
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CHAPTER IV 
NIK REGULATES DRP1 PHOSPHORYLATION AND IS LOCALIZED TO SITES OF 
MITOCHONDRIAL FISSION 
 
4.1 Summary 
Mitochondrial morphology is dynamically regulated by fusion and fission, and 
dysregulation of this process has been implicated in tumorigenesis. In chapter III, we found that 
a novel pool of NIK protein is localized to mitochondria and regulates mitochondrial recruitment 
of Drp1, a key fission regulator, to promotes mitochondrial fragmentation and glioma cell 
invasion. However, effects of NIK kinase activity on tumor progression and mitochondrial 
dynamics remains largely unknown. Here, we show that depletion of NIK in glioma cell results 
in diminished invasion and also results in entangled and clustered mitochondria in perinuclear 
regions, phenotypes that could be restored by reconstituting NIK wild-type, but not kinase-dead 
NIK mutant. In addition, impaired kinase activity of NIK reduces tumor growth in human glioma 
xenograft mouse models. Intriguingly, NIK is accumulated transiently on dividing mitochondria, 
where Drp1 is recruited to mitochondrial constriction sites for fission to occur. Kinase activity of 
NIK is critical to promote phosphorylation of Drp1 at serine 616 residue, but not to interact with 
Drp1. These results provide a cellular mechanism for kinase activity of NIK-mediated 
mitochondrial dynamics leads to constriction at the fission site and tumor growth. 
 
4.2 Introduction 
In non-canonical NF-κB pathway, the fundamental purpose of NIK as serine/threonine 
protein kinase is to phosphorylate IKKα, resulting proteasomal processing of p100 to p52 to 
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regulates the transcription of genes involved in inflammation, development, cell cycle, cell 
proliferation, and cell survival (Ge et al., 2016; McDaniel et al., 2016; Park and Hong, 2016; 
Sun, 2012). While most studies about NF-κB pathway focused on investigating how canonical 
NF-κB/p65-mediated signaling cascade regulates the activity of transcription factors associated 
with various cellular functions, our previous studies identified involvement of NIK-mediated 
non-canonical NF-κB pathway in pseudopodia formation, cell elongation, and invasion of glioma 
cell (Cherry et al., 2015; Duran et al., 2016). Particularly, overexpression of NIK led to 
accelerated tumor growth in a xenograft model, compared to control cells. (Cherry et al., 2015). 
In the previous chapter, we found that mitochondrial NIK is a novel pool of NIK protein in 
cancer cells that regulate mitochondrial dynamics, motility and cell invasion even in the absence 
of the IKK/NF-κB signaling cascade. However, it is still unclear whether kinase activity of NIK 
is required for regulating mitochondrial dynamics and glioma tumorigenesis.  
Phosphorylation of mitochondrial fission regulators such as Drp1 are known to be 
required for their activity or recruitment to mitochondria (Kashatus et al., 2011; Taguchi et al., 
2007). In fact, a phosphodefective mutant Drp1-S616A (serine at 616 was mutated to alanine) 
failed to promote mitochondria fission, which resulted in abnormal mitochondrial morphology 
(Cereghetti et al., 2008). Knockdown of Drp1 expression or the phosphorylation-deficient mutant 
of Drp1 was unable to promote tumor growth (Kashatus et al., 2015; Zhan et al., 2016). It 
strongly suggests that the effect of Drp1 activity involved in mitochondria dynamics and tumor 
progression may depend on upstream kinases (Chang and Blackstone, 2010; Hu et al., 2017). 
Considering that phosphorylation sites tend to be located on binding spots to regulate complex 
formation, activity of fusion and fission molecular machineries to control mitochondrial 
dynamics will be easily influenced by binding partners. Moreover, we identified several potential 
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phosphorylation sites of Drp1 for NIK through the PhosphoNET prediction database, Drp1 - 
S119, S248, S616, and S665 (Fig.47). Although we observed that NIK binds to Drp1 and 
enhances phosphorylation of the key fission regulator, it is still unclear how NIK and Drp1 
collaborate to drive mitochondria division and whether NIK acts directly to phosphorylate Drp1. 
Here, we identified that the kinase activity of NIK maintains mitochondrial dynamics, drives cell 
invasion and tumor growth, and is required for the phosphorylation Drp1. 
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Figure 47. Potential phosphorylation motifs of Drp1 for serine/threonine protein kinase NIK. The potential 
phosphorylation sites (highlighted) were predicted using PhosphoNET prediction database. 
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4.3 Results 
4.3.1 Kinase-dead NIK affects mitochondrial fission and invasion of glioma 
To explore effects of NIK kinase activity on mitochondrial dynamics, we first made 
mouse NIK cDNA construct with point mutations K431A/K432A (corresponds to the 
K429A/K430A mutations in human NIK), which abrogate its kinase activity (de Leon-Boenig et 
al., 2012; Luftig et al., 2001; Tao and Ghosh, 2012). The human glioma BT25 cells lacking a 
functional NIK gene (BT25-sgNIK) were reconstituted with murine NIK wild-type (BT25-
sgNIK+rescue) or kinase-dead mutant (mNIKK431A/K432A; BT25-sgNIK+KD-rescue). The total 
protein levels of non-canonical NF-κB signaling in each BT25 cells were examined by western 
blot using specific antibodies for the subunits of non-canonical NF-κB. As expected, the kinase-
dead mutant of NIK was not able to induce the phosphorylation of IKK/ and the p100 
processing to p52, while the expression levels of the non-canonical NF-κB subunits in BT25-
sgNIK+rescue cells remained similar or higher than that of control cells (Fig. 48A). However, 
the results of experiments showing NIK immunostaining to examine whether kinase-dead mutant 
affects NIK localization reveal that kinase-dead NIK was successfully colocalized with Tim50 as 
a marker to establish the localization of NIK in the mitochondria, similar to wild-type NIK in 
BT25 control cells (Fig. 48B). Consistent with immunostaining results, kinase-dead NIK protein 
was present in both mitochondrial-enriched (M) and cytosolic (C) cell fractions as well as 
endogenous NIK (BT25 control) and reconstituted wild-type NIK (BT25-sgNIK+rescue), 
whereas NIK protein was not detected by immunostaining and immunoblot in either fraction 
from BT25-sgNIK cells (Fig. 48B and 49). 
To determine whether kinase activity of NIK is required for glioma invasion, we 
performed three-dimensional collagen invasion assay. Depletion of NIK expression in BT25-
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sgNIK cells significantly attenuates invasive potential in three-dimensional collagen matrices 
compared with control cells, and the decreased invasion was restored with reconstitution of 
murine wild-type NIK. Interestingly, reconstitution of kinase-dead NIK in BT25-sgNIK (BT25-
sgNIK+KD-rescue) was unable to restore invasion ability compared to BT25-sgNIK+rescue 
(Fig. 50). We also examined changes in mitochondrial morphology due to loss of NIK kinase 
activity. Each structure obtained from Mito-GFP staining was outlined and the area was 
determined by ImageJ morphometric analysis (Fig. 51A). Consistent with previous observation, 
loss of NIK in glioma cell (BT25-sgNIK cells) results in increased mitochondrial size and 
decreased mitochondrial number compared to control cells (Fig. 51B). Importantly, the 
mitochondrial hyperfusion of BT25-sgNIK cells was rescued through reconstitution of wild-type 
NIK (BT25-sgNIK+rescue), but not kinase-dead NIK (BT25-sgNIK+KD-rescue) (Fig. 51B). 
Together, these data demonstrate that the kinase activity of NIK is important for invasion and 
mitochondrial dynamics in glioma cells. 
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Figure 48. Kinase-dead mutant of NIK was not able to promote the non-canonical NF-κB pathway. (A) 
Immunoblot analysis of whole cell lysates prepared from BT25 control, BT25-sgNIK, BT25-sgNIK+rescue and 
BT25-sgNIK+KD-rescue cells pretreated with TWEAK (10 ng/ml) and MG132 (5 μM) to stabilize NIK for facile 
detection. Blots were probed with indicated antibodies. (B) Immunofluorescence images of BT25 control, BT25-
sgNIK, BT25-sgNIK+rescue and BT25-sgNIK+KD-rescue cells immunostained for NIK (Red), Tim50 (green) and 
DAPI (blue). Images marked with white squares are amplified and shown in the insert. Scale bar, 5 μm. 
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Figure 49. Loss of NIK kinase activity does not affect its mitochondrial localization. Immunoblot analysis of 
mitochondrial-enriched (M) and cytosolic (C) fractions prepared from BT25 control, BT25-sgNIK, BT25-
sgNIK+rescue and BT25-sgNIK+KD-rescue cells pretreated with TWEAK (10 ng/ml) and MG132 (5 μM). Four 
times the volume equivalent of mitochondrial-enriched fraction versus cytosol fraction was loaded (mitochondrial-
enriched/cytosol = 4:1). Blots were probed with indicated antibodies. 
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Figure 50. Loss of NIK kinase activity reduces their invasive potential in glioma cells. Quantification of three-
dimensional collagen invasion assays comparing BT25 control, BT25-sgNIK, BT25-sgNIK+rescue and BT25-
sgNIK+KD-rescue cells. Data are represented as mean ± SD. ** p<0.01 (n=6), one-way ANOVA; NS: not 
significant. 
 
 
 
 96 
 
 
 
 
 
 
 
 
 
Figure 51. Kinase-dead mutant of NIK failed to restore mitochondria fission. (A) Mitochondrial number and 
size in BT25 control, BT25-sgNIK, BT25-sgNIK+rescue and BT25-sgNIK+KD-rescue cells were transfected with 
Mito-GFP (Outline), and (B) then quantified using the Analyze Particles function in ImageJ software. Data are 
represented as mean ± SD. ** p<0.01 for sgNIK vs. control; sgNIK vs. sgNIK+rescue; sgNIK+rescue vs. 
sgNIK+KD-rescue. one-way ANOVA (n > 50, respectively); NS: not significant. Scale bar, 10 μm. 
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4.3.2 Impaired kinase activity of NIK reduces tumor growth in vivo xenograft models of 
glioma 
Previously we have reported that NIK overexpression in glioma positively regulates 
tumor growth in vivo (Cherry et al., 2015), suggesting that loss of NIK expression may inhibits 
tumor growth. To examine the roles of kinase activity of NIK in vivo, BT25 control, -sgNIK, -
sgNIK+rescue and -sgNIK+KD-rescue cells were fluorescently labeled with a DiD-fluorescent 
probe to monitor tumor growth and injected intracranially into the brain of CD-1 nude mice. We 
found that suppression of NIK expression (BT25-sgNIK) significantly inhibited intracranial 
tumor growth compared with the mice injected with BT25 control cells (Fig. 52). Particularly, 
the three-dimensional tomographic reconstruction of fluorescent images obtained from in vivo 
imaging system (IVIS) showed that loss of NIK kinase activity (BT25-sgNIK+KD-rescue) 
resulted in reduced tumor size and less invasive tumors compared with BT25-sgNIK+rescue 
cells (Fig. 53). Unexpectedly, tumors derived from kinase-dead NIK cells had become much 
larger then NIK-knockout cells for unknown reasons, it was probably due to transduction-
mediated overexpression of NIK proteins above the threshold value (Fig. 52 and 53). In addition, 
the hematoxylin and eosin (H&E) staining assay was performed to evaluate and to visualize the 
brain tumors. Consistent with results from IVIS analysis, we found that BT25-sgNIK+KD-rescue 
cells diminished tumor formation, by contrast, mice receiving BT25-sgNIK+rescue cells showed 
an increase in tumor size (Fig. 54). These results strongly suggest that NIK kinase activity is 
crucial for tumor growth. 
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Figure 52. Loss of NIK reduces xenograft tumor growth. Representative IVIS images of three-dimensional 
rendering of tumors derived from DiD-labelled intracranial-injected BT25 control and BT25-sgNIK at 30 days post-
injection (n=3 mice per group). Numbers indicate length of three dimension for each image. Right graph showing 
quantification of tumors size. Data represent average tumor volume ± S.E.M. *p < 0.05 for BT25 control vs. BT25-
sgNIK; Unpaired Student’s t-test. 
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Figure 53. Kinase activity of NIK is required for xenograft tumor growth. Representative IVIS images of three-
dimensional rendering of tumors derived from DiD-labelled intracranial-injected BT25-sgNIK+rescue and BT25-
sgNIK+KD-rescue cells at 30 days post-injection (n=3 mice per group). Numbers indicate length of three dimension 
for each image. Right graph showing quantification of tumors size. Data represent average tumor volume ± S.E.M. 
*** p < 0.001 for BT25-sgNIK+rescue vs. BT25-sgNIK+KD-rescue. Unpaired Student’s t-test. 
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Figure 54. H&E staining of xenograft tumor. Representative hematoxylin and eosin (H&E) staining images of 
brain sections from BT25 control, BT25-sgNIK, BT25-sgNIK+rescue and BT25-sgNIK+KD-rescue xenograft 
tumors. Brains were harvested at 5 - 6 weeks after transplantation. Images marked with black squares are amplified 
and shown in the insert. Scale bars: 500 μm. 
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4.3.3 NIK-Drp1 interaction enriches at mitochondrial constriction sites 
In chapter III, we have shown that NIK localizes to mitochondria and binds Drp1 as well 
as its potential to recruit Drp1 from the cytoplasm to mitochondria to promote mitochondrial 
fission. Thus, identifying an exact localization of NIK-Drp1 interaction in glioma cell is essential 
to finding mechanisms underlying mitochondrial fission. We performed live-cell imaging using a 
NIK green fluorescent protein (GFP)-fusion protein (GFP-NIK) to determine whether NIK 
localized at mitochondrial fission sites. First, functionality of the NIK protein after GFP-tagging 
was confirmed by western blot analysis that transiently expressed GFP-NIK activates non-
canonical NF-κB pathway including p100 processing, p52 nuclear translocation and 
phosphorylation of IKKα/β, similar to non GFP-tagged NIK (Fig. 55). Time-lapse imaging 
assays revealed that GFP-NIK recruits and accumulates transiently at the outer surface of 
mitochondrial division sites from the non-constricted sites, and then released from the 
constriction sites immediately after fission (Fig. 56).  
Considering that a key fission regulator Drp1 is primarily localized to the cytoplasm and 
recruited to mitochondrial constriction sites immediately prior to fission (Frank et al., 2001; 
Smirnova et al., 2001), NIK enrichment at construction sites is most likely necessary for Drp1 
recruitment and interaction with Drp1. Therefore, an in situ proximity ligation assay (in situ 
PLA), a highly specific protein interaction screening method (Fredriksson et al., 2002), was 
employed to determine whether endogenous NIK binds Drp1 at mitochondria in glioma cell. The 
in situ PLA experiment showed that interactions between NIK and Drp1 were predominantly 
observed in mitochondria, as indicated by most PLA signals localized on mitochondrial marker 
Tom20, and are rarely found in cytosol (Fig. 57). To confirm that these signals were indeed 
specific, in situ PLA was performed using immunoglobulin G as a negative control or PGAM5, 
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which is known to interact with Drp1 (Xu et al., 2015), as a positive control. As expected, IgG 
control did not produce any PLA signals in the cells as well as BT25-sgNIK cells (Fig. 58A and 
C), while a number of distinct fluorescent dots are observed in assay using PGAM5 and Drp1 
antibodies (Fig. 58B). This endogenous protein-protein interaction was also verified by 
immunofluorescence staining using NIK and Drp1 antibody and immunoprecipitation for Drp1 
in TWEAK/MG132-treated BT25 cells (Fig. 59). Wild-type NIK, reconstituted NIK or kinase-
dead mutant NIK all colocalized and associated with Drp1, indicating that NIK-Drp1 interaction 
was independent of kinase activity (Fig. 59). We further assessed the involvement of NIK and 
Drp1 on the division event by live-cell imaging using mCherry-tagged Drp1 (mch-Drp1) and 
GFP-NIK in glioma cells. We found that mCh-Drp1 puncta were recruited transiently at 
constriction site and colocalized with GFP-NIK around the outer surface of mitochondrial fission 
site (Solid arrows in Fig. 60). Particularly, GFP-NIK was recruited to future constriction sites 
prior to Drp1 recruitment to trigger mitochondrial constriction (hollow arrows in Fig. 60). 
Recruitment of NIK and Drp1 into mitochondrial fission sites was also observed in non-
cancerous COS-7 cells (Fig. 61 and 62). These results suggest that NIK enriched at 
mitochondrial constriction site may play an important role in initiation of mitochondria fission 
through interaction with Drp1. 
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Figure 55. Validation of NIK-GFP fusion protein function. Western blot analysis of cytosolic and nuclear 
fractions isolated from 293T transiently expressing GFP-empty vector (control) and (A) HA-NIK or (B) GFP-NIK. 
Blots were probed with the indicated antibodies.  
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Figure 56. NIK accumulates at mitochondrial constriction sites in glioma cells. Time-lapse image of BT25 cell 
transiently expressing mito-BFP (blue) and GFP-NIK (green) acquired with every 5 sec intervals for 3 min. Line-
scan analysis shows fluorescence intensity of GFP-NIK along a portion of indicated fission site. Images were 
threshold-adjusted by subtracting background GFP in the cytosol, followed by deconvolution. Yellow arrow 
indicates fission site. Scale bar, 1 μm. 
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Figure 57. Interactions between NIK and Drp1 are predominantly localized in mitochondria. BT25 cells were 
stained for endogenous NIK and Drp1, followed by ligation and amplification (Red) of PLA probes minus and plus, 
and then immunostained for Tom20 (green) and DAPI (blue). Images marked with white squares are magnified and 
shown as three-dimensional projections (3D). Scale bar, 2 μm.  
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Figure 58. Validation of specificity of proximity ligation assay. (A) BT25 cells were stained with endogenous 
Drp1 and control IgG or PGAM5, followed by ligation and amplification (Red) of PLA probes minus and plus, and 
then immunostained for DAPI (blue) (B) Mito-GFP labelled BT25-sgNIK cells were subjected to in situ proximity 
ligation assay with NIK and Drp1 antibody. Scale bar, 5 μm. 
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Figure 59. NIK–Drp1 interaction is independent of NIK kinase activity.  (A) Immunofluorescence images of 
BT25 control, BT25-sgNIK, BT25-sgNIK+rescue and BT25-sgNIK+KD-rescue cells immunostained for NIK 
(Green), Drp1 (red) and DAPI (blue). Images marked with white squares are amplified and shown in the insert. 
Scale bar, 5 μm. (B) BT25 control, BT25-sgNIK, BT25-sgNIK+rescue and BT25-sgNIK+KD-rescue cell lysates 
were subjected to immunoprecipitation (IP) with control IgG or a Drp1 antibody, and then analyzed by 
immunoblotting with the indicated antibodies.  
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Figure 60. NIK-Drp1 interaction accumulates at mitochondrial constriction sites in glioma cells. Time-lapse 
image of BT25 cell transiently expressing mito-BFP (blue), mch-Drp1 (red) and GFP-NIK (green) acquired with 
every 5 sec intervals for 3 min. Line-scan analysis shows fluorescence intensity of mch-Drp1 and GFP-NIK along a 
portion of indicated fission site. Images were threshold-adjusted by subtracting background GFP in the cytosol, 
followed by deconvolution. Arrows denote: yellow arrows (fission site; amplified and shown in the lower right 
corner); hollow arrowheads (co-localization of mch-Drp1 and GFP-NIK); hollow arrow (beginning of constriction; 
amplified and shown in the upper left corner).  Scale bar, 1 μm. 
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Figure 61. NIK recruits to mitochondrial constriction sites in COS-7 cells. Time-lapse image of COS-7 cell 
transiently expressing mito-BFP (blue) and GFP-NIK (green) acquired with every 5 sec intervals for 3 min. Line-
scan analysis shows fluorescence intensity of GFP-NIK along a portion of indicated fission site. Images were 
threshold-adjusted by subtracting background GFP in the cytosol, followed by deconvolution. Yellow arrow with 
red circle indicates fission site. Scale bar, 1 μm. 
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Figure 62. NIK recruits to mitochondria and interacts with Drp1 at constriction sites in COS-7 cells. Time-
lapse image of COS-7 cell transiently expressing mito-BFP (blue), mch-Drp1(red) and GFP-NIK (green) acquired 
with every 5 sec intervals for 3 min. Line-scan analysis shows fluorescence intensity of GFP-NIK along a portion of 
indicated fission site. Images were threshold-adjusted by subtracting background GFP in the cytosol, followed by 
deconvolution. Images marked with yellow arrows are amplified and shown in the insert. Arrows denote: yellow 
arrows (fission site); arrowheads (co-localization of mch-Drp1 and GFP-NIK).  Scale bar, 1 μm. 
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4.3.4 NIK promotes phosphorylation of Drp1 
Drp1 activity is regulated by post-translational modification, particularly phosphorylation 
at serine residue 616 (S616) is necessary to promote mitochondrial fission (Jahani-Asl and Slack, 
2007; Prieto et al., 2016; Taguchi et al., 2007). We therefore investigated whether NIK regulates 
Drp1 activity through phosphorylation of S616. Immunofluorescence analyses showed that 
puncta of Drp1 phosphorylation at S616 (p-S616) were localized mostly in the mitochondria in 
BT25 control cells (Fig. 63). The number of Drp1 p-S616 puncta were significantly decreased in 
BT25-sgNIK cells, but it was restored in BT25-sgNIK+rescue cells (Fig. 63). Interestingly, 
kinase-dead mutant of NIK (BT25-sgNIK+KD-rescue), unlike wild-type NIK, failed to restore 
the increased p-S616 staining (Fig. 63). Biochemical fractionation analyses also confirmed that 
the total level of Drp1 phosphorylation at S616 was decreased in BT25-sgNIK cells (Fig. 64). 
Compared to BT25-sgNIK+rescue cells, BT25-sgNIK+KD-rescue cells exhibited substantially 
diminished phosphorylation of Drp1-S616 (Fig. 63 and 64), but the kinase-dead mutant of NIK 
does not significantly affect the efficiency of Drp1 mitochondrial recruitment (Fig. 64, 65 and 
66). Unpredictably, relatively lower levels of mitochondrial Drp1 phosphorylation at S616 was 
detected by fractionation analysis (Fig. 64), while immunostaining showed that Drp1 p-S616 
staining is mostly colocalized with a mitochondria marker (Fig. 63). This discrepancy may be 
due to weak association of Drp1 with mitochondria membrane, which is easily lost during the 
fractionation procedure.  
To test whether kinase activity of NIK is responsible for phosphorylation of Drp1-S616, 
we first performed an in vitro kinase assay using cell lysates as sources of the kinase. The cell 
extracts from 293T cells transfected with a construct expressing NIK wild-type or NIKK429A/K430A 
were incubated with purified glutathione S-transferase (GST)-Drp1 as a substrate, and we found 
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that only lysates of 293T cells transfected with NIK wild-type phosphorylates Drp1-S616 (Fig. 
67A). Similar results were also observed with immunoprecipitates from the cell lysates. NIK 
proteins are isolated with antibody-coupled magnetic beads, and then performed in vitro kinase 
assay using the purified GST-Drp1. We observed that Drp1-S616 was phosphorylated by bead-
bound NIK wild-type, but neither bead-bound NIKK429A/K430A nor bead control (Fig. 67B). Taken 
together, these results indicate that NIK is responsible for Drp1-S616 phosphorylation, which 
promotes mitochondrial fission. 
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Figure 63. NIK influences phosphorylation of Drp1-S616. BT25 control, BT25-sgNIK, BT25-sgNIK+rescue and 
BT25-sgNIK+KD-rescue cells immunostained for p-Drp1 S616 (green), Tim50 (red) and DAPI (blue). Images 
marked with white squares are amplified and shown on the right. Scale bar, 5 μm. 
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Figure 64. Kinase-dead mutant of NIK reduces phosphorylation of Drp1-S616. Immunoblot analysis of 
mitochondrial-enriched (M) and cytosolic (C) fractions prepared from BT25 control, BT25-sgNIK, BT25-
sgNIK+rescue and BT25-sgNIK+KD-rescue cells were performed with indicated antibodies. 
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Figure 65. Kinase-dead mutant of NIK doesn't affect mitochondrial association of Drp1. BT25 control, BT25-
sgNIK, BT25-sgNIK+rescue and BT25-sgNIK+KD-rescue cells were transfected with Mito-RFP to visualize 
mitochondria (red) and then immunostained for Drp1 (green), and DAPI (blue). Areas within white squares are 
amplified and shown on the right. Scale bar, 5 µm. 
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Figure 66. Kinase activity of NIK is not required for Drp1 mitochondrial recruitment. Immunoblot analysis of 
mitochondrial-enriched (M) and cytosolic (C) fractions prepared from BT25 control, BT25-sgNIK, BT25-
sgNIK+rescue and BT25-sgNIK+KD-rescue cells was performed with indicated antibodies. Results are 
representative of 4 separate experiments. Bar graph shows quantification of the ratio of Drp1 in cytosolic and 
mitochondria-enriched fractions. Mean ± SD. ** p<0.01 for control vs. sgNIK; NS (not significant) for control vs. 
sgNIK+rescue and control vs. sgNIK+KD-rescue, one-way ANOVA.  
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Figure 67. NIK phosphorylates Drp1 in vitro. 293T cells were transfected with HA-NIK wild-type (WT) or 
kinase-dead mutant K429A/K430A (KD) expression vectors. Cell lysates were immunoprecipitated with anti-HA 
antibody, and the whole cell lysates (A) or immunocomplexes (B) as a source of kinase were subjected to the in 
vitro kinase assay with GST-Drp1 in the absence or presence of 20μM ATP for 15 min at 37 °C. Blots were probed 
with the indicated antibodies. 
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CHAPTER V 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1 NIK promotes tumor cell invasion by regulating mitochondrial dynamics 
The present study establishes several novel features of NIK in cancer cells. We identify a 
previously unrecognized pool of NIK protein in mitochondria and demonstrate that NIK 
regulates Drp1 activity and distribution to control mitochondria dynamics, and ultimately, cancer 
cell morphology and invasiveness. Moreover, these functions and localization of NIK in 
mitochondria do not require the known NIK targets IKK and IKK, and hence, are very likely 
independent of NF-B signaling. 
Based on biochemical cell fractionation and immunofluorescence staining experiments, 
we propose that NIK exists in at least two protein pools: a proteasome-associated cytosolic pool 
primarily mediating IKK/NF-B signaling and a mitochondrial pool regulating Drp1 recruitment 
and mitochondrial dynamics (Fig. 68). The discovery of a discrete mitochondria-associated 
fraction of NIK was unexpected, given that NIK has been described primarily as cytosolic 
protein that is constitutively degraded in the absence of stimuli (Sun, 2012). Indeed, this property 
renders endogenous NIK difficult to detect by immunoblot under basal conditions and in the 
absence of proteasome inhibition (Fig. 12D and 39B). Regardless, distinct NIK immunostaining 
is observed in mitochondria, even under unstimulated conditions in different cancer cell lines, as 
                                                 

Part of this chapter is reprinted with permission from “NIK/MAP3K14 Regulates Mitochondrial Dynamics and 
Trafficking to Promote Cell Invasion.” By Jung JU, Ravi S, Lee DW, McFadden K, Kamradt ML, Toussaint LG, 
Sitcheran R, 2016. Current Biology, 26, 3288-3302, Copyright 2016 by Elsevier Ltd. 
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well as immortalized MEFs. NIK mitochondrial localization was observed in MEFs and all 
cancer cells examined using two different antibodies (Fig. 10), and their specificity was verified 
by loss of signal in NIK knockout cells. Most importantly, both the mitochondrial defects and 
NIK mitochondrial localization in NIK knockout cells were rescued by expression of mNIK. We 
surmise that the discrepancy between immunoblot analysis, which detects both cytosolic and 
mitochondrial NIK, and immunofluorescence, may be due to differences in the ability of the 
antibodies to interact with the NIK epitope in its native confirmation in different cellular 
compartments. For example, factors present in the cytosol, but absent in mitochondria, might 
associate with NIK and either alter its conformation or sequester its epitope, thereby preventing 
interaction between the antibody and NIK. In support of this interpretation, one Drp1-specific 
antibody also recognizes only mitochondria-associated, but not cytosolic, Drp1 (Fig. 24). 
Alternatively, the majority of soluble, cytosolic NIK may be lost during the immunostaining 
procedure. NIK detection in the mitochondria by immunofluorescence may also be enhanced by 
its oligomerization at this site. Similar to Drp1, whose oligomerization is critical for its fission-
promoting activity (Ji et al., 2015), NIK is capable of forming homotypic oligomers (Lin et al., 
1998), for which a biological function has not yet been established. While our studies have 
unambiguously identified a pool of NIK in mitochondria, we can not rule out the possibility that 
some NIK protein may localize with other organelles, such as peroxisomes, the ER, the 
mitochondria-associated membrane (MAM) (Schrader et al., 2015) or mitochondrial-derived 
vesicles (MDV) (Sugiura et al., 2014). In this context, we note that a relatively small fraction of 
NIK was reported to co-localize with Rab5+ endosomes in human endothelial cells (Jane-wit et 
al., 2015). However, in cancer cells, NIK does not co-localize with Rab5 (Fig. 11), or ER 
 120 
 
markers (Fig. 10A and 11A). Thus, it is possible that NIK has distinct roles and subcellular 
localizations in different cell types. 
Because NIK lacks a mitochondrial targeting sequence (MTS), it is likely recruited to, 
and retained in, the mitochondria through interactions with a protein containing an MTS (Omura, 
1998). Potential candidates include the mitochondrial Hsp90, which is not only a known 
chaperone of NIK (Qing et al., 2007), but was also found to deliver proteins to mitochondrial 
import receptors (Fan et al., 2006; Young et al., 2003). Alternatively, mitochondrial localization 
of NIK may involve localized, co-translational mitochondrial import (Lesnik et al., 2015), which 
would potentially facilitate its protection from being immediately ubiquitinated and degraded. 
Localization of NIK to mitochondria, its presence in a complex with Drp1, and its regulatory role 
in Drp1 activity and mitochondrial localization suggests that NIK functions as a novel fission 
“sensor”. Thus, it will be interesting to determine whether the association of NIK with 
mitochondria is dynamic, and possibly induced by specific signals known to promote fission 
(Frank et al., 2001; Taguchi et al., 2007; Wang et al., 2012; Willems et al., 2015). 
Our imaging studies have identified a role for NIK in regulating the velocity and 
anterograde movement of mitochondria towards the periphery of migrating cells, suggesting that 
increased fission, mitochondrial motility and cell invasion are functionally linked. This 
hypothesis is supported by the striking phenotype of diverse cancer cells and MEFs lacking NIK, 
which exhibit less fragmented mitochondria that are concentrated in the perinuclear region (Fig. 
8B, 14A, 15A, 16B, 19B, 36A, 43A, 44A). It remains to be investigated whether NIK may 
regulate the motor proteins on the mitochondrial surface, such as kinesin and Miro (Wang and 
Schwarz, 2009). Additionally, in light of recent findings demonstrating a critical role for ER-
associated actin in regulating mitochondrial fission (Friedman et al., 2011; Ji et al., 2015), future 
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studies are necessary to address whether NIK is involved in establishing contacts between 
mitochondria and the ER at sites of fission, or regulating calcium flux, which was recently 
demonstrated to be required for cancer cell migration (Tosatto et al., 2016). 
The recruitment of Drp1 to mitochondria is mediated by several mitochondrial outer 
membrane proteins including mitochondrial fission factors Mff and Fis1 (Loson et al., 2013; 
Otera et al., 2010; Yamada et al., 2016). Mff-null and Fis1-null cells appear interconnected, yet 
elongated (Liu and Chan, 2015), while mitochondria in cells lacking NIK appear tangled and 
collapsed within the perinuclear region, similar to Drp1-null cells (Fig. 8B and 35B).  We also 
note the presence of circularized mitochondria in glioma cells lacking NIK (Fig. 19B), which is 
indicative of mitochondrial damage and stress (Ahmad et al., 2013). These results suggest that 
NIK may regulate other mitochondrial functions, and indeed, we have observed that loss of NIK 
decreases ROS and oxygen consumption, similar to cells lacking Drp1 (Fig. 28 and 29). 
Although we found that NIK forms a complex with Drp1 and affects Drp1 
phosphorylation (Fig. 27 and 32), it remains unclear exactly how NIK mediates Drp1 
phosphorylation. It was recently reported that Erk2 (also known as MAPK1) promotes 
tumorigenesis through phosphorylation of Drp1 S616, resulting in increased mitochondrial 
fission activity (Kashatus et al., 2015). Thus, it's possible that NIK as a serine/threonine protein 
kinase may regulate Drp1 phosphorylation directly through its interaction or indirectly through 
its ability to phosphorylate Erk (Nemoto et al., 1998). Additionally, the increase of Drp1-P637 
observed in BT25-sgNIK cells suggests that NIK may regulate a phosphatase that 
dephosphorylates Drp1. Indeed, a recent study of the NIK interactome identified several 
mitochondrial membrane proteins, including PGAM5, a Drp1-P637 phosphatase (Willmann et 
al., 2016). Alternatively, NIK may regulate Drp1 at other steps, such as oligomeric maturation (Ji 
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et al., 2015), or GTP hydrolysis (Francy et al., 2015). Future studies are needed to clarify these 
molecular mechanisms. 
Lastly, we propose that NIK’s function in mitochondria is independent of IKK/NF-B 
signaling because it supports an expansive mitochondria network, promotes Drp1 mitochondrial 
recruitment and enhances invasive potential in the absence of IKK or IKK (Fig. 38, 40, and 
42). To our knowledge, this is the first report of IKK-independent functions for NIK in cancer. 
However, our data do not exclude the possibility that other mitochondrial functions of NIK may 
involve regulation by the IKK/NF-B axis, particularly in light of previous studies identifying 
other NF-B proteins localized to mitochondria (Cogswell et al., 2003), NF-B-dependent 
control of mitochondrial biogenesis (Bakkar et al., 2012; Zeng et al., 2015), IKK-dependent 
regulation of the fusion protein Opa1 (Laforge et al., 2016), and NIK-IKK association with 
mitochondrial antiviral signaling (MAVS) in response to viral infection (Liu et al., 2008). In this 
study, we have uncovered new roles for NIK in regulating mitochondrial dynamics and tumor 
cell invasion independently of IKK/NF-κB, highlighting the emerging importance of NIK 
signaling in cancer. 
 
5.2 NIK regulates Drp1 phosphorylation and is recruited to mitochondria constriction sites 
In chapter IV, we investigated the molecular mechanism by which NIK regulates 
mitochondria fission and tumor growth. We found first that kinase deficiency mutation of NIK 
(mNIKK431A/K432A) in patient-derived glioma cells decreased the mitochondria fission as well as 
NIK-deficient cells. Second, the kinase-dead mutant NIK was unable to rescue the tumorigenic 
phenotypes of NIK, which promote invasion into three-dimensional collagen I matrices and 
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xenograft tumor growth of glioma cells, compared with wild-type NIK. Third, NIK interacted 
with Drp1 predominantly in mitochondria constriction sites, where NIK may regulate Drp1 
phosphorylation and thus promoting mitochondria fission. 
Abolishment of non-canonical NF-κB activation in reconstitution of mNIKK431A/K432A in 
NIK-deficient glioma cells (BT25-sgNIK+KD-rescue cells) was remarkably similar to that of 
loss of function model derived by NIK knock-out (BT25-sgNIK cell) (Fig. 48A), supporting the 
view for NIK as a critical kinase in the non-canonical NF-κB pathway (de Leon-Boenig et al., 
2012; Luftig et al., 2001).  The mitochondria morphology in BT25-sgNIK+KD-rescue cells also 
resembles hyperfused mitochondria features of BT25-sgNIK cells, which appeared more tangled 
and fused within the perinuclear region (Fig. 48B). Intriguingly, NIK was successfully 
colocalized with mitochondria marker and detected in the mitochondrial fraction, regardless its 
kinase activity (Fig. 48 and 49). However, NIK kinase-dead mutant failed to restore normal 
mitochondria morphology in BT25-sgNIK, while wild-type NIK was able to re-establish that 
increase in number and decrease in size of mitochondria, compare to BT25-sgNIK and BT25-
sgNIK+KD-rescue cells (Fig. 51). These observations suggest that NIK regulates mitochondria 
fission of glioma cells through its kinase activity resided in mitochondria. 
In addition to aberrant mitochondrial dynamics, the BT25-sgNIK+KD-rescue cells 
display loss of tumorigenic phenotypes that were observed in BT25 control and BT25-
sgNIK+rescue cells. We previously observed a reduced invasive potential in NIK-deficient 
glioma cells, by contrast, overexpression of NIK increased glioma cell invasion (Cherry et al., 
2015; Duran et al., 2016). The invasion ability of glioma cells was significantly diminished in 
BT25-sgNIK+KD-rescue cells, but not BT25-sgNIK+rescue cells, suggesting that loss of NIK 
kinase activity contributes to this deficit (Fig. 50). Therefore, similar results observed in BT25-
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sgNIK cells that may be caused fundamentally by absence of serine/threonine protein kinase 
function of NIK (Fig. 50). 
Previously, studies have demonstrated that targeting Drp1 using genetic or 
pharmacological inhibition constrained tumorigenesis of glioma, melanoma, and breast cancer 
(Wieder et al., 2015; Xie et al., 2015; Zhao et al., 2013). Similar results were also observed in 
BT25-sgNIK cells (Fig. 52). Nevertheless, the biological significance of NIK kinase activity in 
regulation of tumor progression is poorly understood. Interestingly, the kinase-dead mutant of 
NIK resulted in significant reduction of tumor volume in a glioma xenograft model in mice 
compared with BT25-sgNIK cells expressing wild-type NIK, indicating that loss of NIK kinase 
activity is accompanied by a reduced intracranial tumorigenesis in vivo (Fig. 53 and 54). 
However, these results do not exclude IKK/NF-κB axis’s contribution in tumorigenic features 
including invasion and growth of tumor. In fact, non-canonical NF-κB pathway including IKKα 
and RelB have been shown to contribute to development of tumors (Cao et al., 2007; Wang et 
al., 2016). Considering the previous observation that overexpression of NIK in cells lacking 
IKKα and IKKβ, key downstream targets of NIK, increased mitochondria fission and cell 
invasion (Fig. 40 and 43), kinase activity of NIK must be at least necessary not only for 
activation of NF-κB signaling, but also for additional factors involved in these events to promote 
malignancy. We thus propose that kinase activity of NIK is required for tumorigenesis in glioma 
cells. 
Intriguingly, NIK is accumulated to mitochondria constriction sites prior to division 
event, strongly suggesting a potential involvement of NIK in mitochondria fission (Fig. 56 and 
61). The fission event requires the function of Drp1, which is translocated from the cytosol to the 
pre-determined sites on mitochondria that subsequently generates the mechanical force to 
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promote membrane scission (Otera et al., 2013; Smirnova et al., 2001). Indeed, live cell imaging 
revealed that Drp1 and NIK puncta were recruited and accumulated transiently at constriction 
site (Fig. 60 and 62), particularly NIK is recruited to the pre-determined sites, which is followed 
by subsequent Drp1 undergoes mitochondrial recruitment and transiently colocalized to NIK 
within the constriction sites (Fig. 60). This result is supported by biochemical cell fractionation 
and in situ PLA experiments that NIK enhances mitochondrial recruitment of Drp1 and the NIK-
Drp1 interactions are predominantly localized in mitochondria (Fig. 25 and 57), whereas NIK 
does not bind to Drp1-related mitochondrial dynamic regulators and MIM protein (Fig. 33). We 
also speculate that NIK might be required for Drp1-independent initial constriction events, 
because NIK undergoes mitochondrial recruitment prior to recruitment of Drp1 (hollow arrows 
in Fig. 60). This view is in line with some studies that Drp1 recruitment and mitochondrial 
constriction are distinct processes (Legesse-Miller et al., 2003), and inverted formin-2 (INF2) on 
the ER membrane drives initial constriction of mitochondria through promoting actin 
polymerization (Friedman et al., 2011; Korobova et al., 2013). The actin polymerization 
promotes myosin II recruitment and constriction, resulting in Drp1 accumulation and fission 
(Korobova et al., 2014). Therefore, as suggested by the previous chapter, further investigations 
are necessary to address the possible hypothesis that NIK may regulate ER-associated actin in 
driving constriction. 
To date, many studies have been identified multiple serine/threonine protein kinases such 
as PKA, CDK, and Erk2 for Drp1 phosphorylation (Chang and Blackstone, 2007a; Cho et al., 
2014; Cribbs and Strack, 2007; Prieto et al., 2016; Strack et al., 2013). Phosphorylation at 
Ser616 of Drp1 has been implicated in promoting mitochondrial fission and tumor growth 
(Kashatus et al., 2015). In this study, we observed a marked decrease in phosphorylation at S616 
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in glioma cells lacking NIK (BT25-sgNIK) or expressing NIK kinase-dead mutant (BT25-
sgNIK+KD-rescue) (Fig. 63 and 64). Unexpectedly, the results obtained from two different 
analyses showed the different quantitative patterns of phosphorylation of Drp1-S616 that puncta 
of Drp1-S616 phosphorylation in immunofluorescence staining were largely localized in 
mitochondria, while high levels of the phosphorylated protein were detected in cytosolic 
fractions by biochemical fractionation analysis (Fig. 63 and 64). These differences are likely 
related to a transient recruitment of Drp1, which probably bind transiently to the MOM (Otera et 
al., 2010; Otsuga et al., 1998; Smirnova et al., 1998). Consequently, mitochondrial 
phosphorylated Drp1 may be unstable after mitochondria fission events and may easily lose its 
association with the mitochondria. NIK-mediated Drp1 activation is also confirmed by in vitro 
kinase assay using the purified Drp1 as a substrate, showing that the purified protein is 
phosphorylated at serine 616 by wild-type NIK, but not by kinase-dead mutant NIK (Fig. 67). 
Importantly, the kinase-dead NIK protein can still associate with Drp1 (Fig. 59), thus excluding 
the possibility that its incapability to regulate phosphorylation of S616 is due to lack of 
association with Drp1. We therefore propose that the kinase activity of NIK is responsible for 
phosphorylation of Drp1-S616. 
In light of these observations, we suggest that NIK-Drp1 interaction may result in 
enrichment of active Drp1 in mitochondrial constriction sites and influence mitochondria 
dynamics to promote tumorigenic potential of glioma. So, it would be interesting in future 
studies to investigate which domain or motif in NIK interacts with Drp1 and how the interaction 
is regulated for mitochondria dynamics. 
In conclusion, my dissertation studies demonstrate the novel mechanisms of NIK-
mediated tumor progression. We propose a working model that NIK kinase activity in glioma 
 127 
 
cells is required for tumorigenesis through regulating phosphorylation of Drp1, which activates 
mitochondrial fission (Fig. 68B). These findings may help to explain the complexity of NIK 
behavior in promoting tumor progression and establish therapeutic interventions to malignant 
tumors. 
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Figure 68. Model depicting NIK function in mitochondria. Model depicts two distinct pools of NIK protein that 
regulate IKK-dependent NF-κB signaling and IKK-independent mitochondrial dynamics. (A) Cytosolic NIK is 
constitutively degraded in resting cells, while signal-induced stabilization regulates downstream IKK complexes to 
activate NF-κB signaling. (B) NIK is localized to mitochondria and regulates Drp1 phosphorylation and recruitment 
to mitochondria constriction sites, resulting in increased mitochondrial fission, motility and distribution throughout 
the cell, as well as enhanced tumorigenesis, in a manner that is independent of IKK/NF-κB signaling. 
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